KR20200136721A - Composition for preventing or treating woman menopause symptoms comprising Cordyceps militaris Concentrate as an active ingredient - Google Patents
Composition for preventing or treating woman menopause symptoms comprising Cordyceps militaris Concentrate as an active ingredient Download PDFInfo
- Publication number
- KR20200136721A KR20200136721A KR1020190062648A KR20190062648A KR20200136721A KR 20200136721 A KR20200136721 A KR 20200136721A KR 1020190062648 A KR1020190062648 A KR 1020190062648A KR 20190062648 A KR20190062648 A KR 20190062648A KR 20200136721 A KR20200136721 A KR 20200136721A
- Authority
- KR
- South Korea
- Prior art keywords
- cordyceps militaris
- concentrate
- menopausal symptoms
- preventing
- pharmaceutical composition
- Prior art date
Links
- 241001264174 Cordyceps militaris Species 0.000 title claims abstract description 124
- 239000012141 concentrate Substances 0.000 title claims abstract description 100
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 239000004480 active ingredient Substances 0.000 title claims description 16
- 230000009245 menopause Effects 0.000 title abstract description 27
- 208000024891 symptom Diseases 0.000 title abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 8
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 238000000605 extraction Methods 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 37
- 239000002904 solvent Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229940088597 hormone Drugs 0.000 claims description 18
- 239000005556 hormone Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 14
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims description 13
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims description 5
- 208000026139 Memory disease Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 4
- 208000006820 Arthralgia Diseases 0.000 claims description 4
- 206010065941 Central obesity Diseases 0.000 claims description 4
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000006984 memory degeneration Effects 0.000 claims description 4
- 208000023060 memory loss Diseases 0.000 claims description 4
- 230000027939 micturition Effects 0.000 claims description 4
- 208000013465 muscle pain Diseases 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 230000035900 sweating Effects 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 241000190633 Cordyceps Species 0.000 claims description 3
- 206010016825 Flushing Diseases 0.000 claims description 3
- 239000005909 Kieselgur Substances 0.000 claims description 3
- 206010029216 Nervousness Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 206010068313 Urethral atrophy Diseases 0.000 claims description 3
- 206010046914 Vaginal infection Diseases 0.000 claims description 3
- 201000008100 Vaginitis Diseases 0.000 claims description 3
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 230000037182 bone density Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000036620 skin dryness Effects 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 230000006403 short-term memory Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 41
- 208000008589 Obesity Diseases 0.000 abstract description 21
- 235000020824 obesity Nutrition 0.000 abstract description 21
- 238000010171 animal model Methods 0.000 abstract description 16
- 210000000579 abdominal fat Anatomy 0.000 abstract description 7
- 230000001076 estrogenic effect Effects 0.000 abstract description 7
- 235000005911 diet Nutrition 0.000 abstract description 4
- 230000037213 diet Effects 0.000 abstract description 4
- 235000008504 concentrate Nutrition 0.000 description 90
- 210000004027 cell Anatomy 0.000 description 21
- 229940011871 estrogen Drugs 0.000 description 21
- 239000000262 estrogen Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 18
- 230000006698 induction Effects 0.000 description 15
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 13
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 12
- 102100038595 Estrogen receptor Human genes 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000004663 cell proliferation Effects 0.000 description 12
- 230000036541 health Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000002611 ovarian Effects 0.000 description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 8
- 208000021017 Weight Gain Diseases 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 102000015694 estrogen receptors Human genes 0.000 description 8
- 108010038795 estrogen receptors Proteins 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 210000001672 ovary Anatomy 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 7
- 238000009806 oophorectomy Methods 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 230000005754 cellular signaling Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002657 hormone replacement therapy Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- -1 for example Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 229960002258 fulvestrant Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 동충하초(Cordyceps militaris) 농축액을 유효성분으로 포함하는 여성 갱년기 증상 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating women's menopausal symptoms, comprising a concentrate of Cordyceps militaris as an active ingredient.
여성의 갱년기는 40~50 대에 나타나며, 난소의 노화로 인한 에스트로겐 즉, 여성 호르몬의 분비 감소에 기인하며, 폐경을 전후로 약 2~10 년에 걸쳐 나타난다.Women's menopause occurs in their 40s to 50s, and is due to a decrease in the secretion of estrogen, that is, female hormones due to aging of the ovaries, and appears over 2-10 years before and after menopause.
여성의 갱년기에 의한 증상은 다섯 가지 분류로 구분되며, 구체적으로 첫째 혈관성 변화에 의한 증상으로 안면홍조, 빈맥, 발한, 두통이 있고, 둘째 근골격계 변화에 의한 증상으로 근육통, 관절통, 요통이 있으며, 셋째 비뇨생식기 변화에 의한 증상으로 빈뇨, 뇨실금이 있고, 넷째 뇌신경계 변화에 의한 증상으로 기억력 감퇴, 우울증, 집중력 감퇴, 현기증이 있으며, 다섯째 일반적 변화에 의한 증상으로 시력 감퇴, 피부 및 모발의 변화가 있다.Symptoms due to menopause in women are classified into five categories. Specifically, first, symptoms due to vascular changes include facial flushing, tachycardia, sweating, and headache, second symptoms due to changes in the musculoskeletal system include muscle pain, joint pain, and low back pain, and third. Symptoms due to genitourinary changes include frequent urination and urinary incontinence. Fourth, symptoms due to changes in the cranial nervous system include memory loss, depression, decreased concentration, and dizziness.Fifth, symptoms due to general changes include decreased vision, changes in skin and hair have.
상기 여성 갱년기 증상들은 정도의 차이는 있으나, 폐경 전·후 여성의 약 80%가 경험하고 있다. 무엇보다도 주목할 만한 사실은 갱년기를 거치면서 여성의 생명에 영향을 미치는 중요한 변화가 장기간에 걸쳐 발생하는데 그것은 골다공증과 심혈관계 질환의 발생 위험성 증가이다. 이러한 여성 갱년기 증상들을 고려해 볼 때 갱년기 증후군이 중년 여성들의 신체적, 정신적 건강 및 삶의 질적인 면에서 지대한 영향을 미침을 알 수 있다. 따라서, 이를 치료할 수 있는 방법이 절대적으로 필요하다.There are differences in degrees of the above female menopausal symptoms, but about 80% of women before and after menopause experience them. Most notably, significant changes that affect women's life through menopause occur over a long period of time, which is an increased risk of osteoporosis and cardiovascular disease. Considering these women's menopausal symptoms, it can be seen that the menopausal syndrome has a profound effect on the physical and mental health and quality of life of middle-aged women. Therefore, there is an absolutely need for a way to treat it.
종래에는 여성의 갱년기 증상을 치료하기 위하여, 호르몬 대체요법, 비스테로이드계 제제 및 골다공증 치료를 위한 약물 치료법 등이 개발되었고, 이중에서 지금까지 가장 효과적으로 알려진 방법은 호르몬 대체요법이다.Conventionally, in order to treat women's menopausal symptoms, hormone replacement therapy, nonsteroidal preparations, and drug therapy for osteoporosis have been developed, and among them, the most effective method known so far is hormone replacement therapy.
「호르몬 대체요법」은 폐경 여성에서 여성 호르몬의 결핍으로 인하여 나타나는 증상을 경감시키기 위하여 여성 호르몬을 투여하는 치료법을 의미한다. 여성 호르몬을 단독으로 투여하는 경우 자궁내막 증식이 발생할 수 있어 보통 황체호르몬을 병합 투여한다.“Hormone replacement therapy” refers to a treatment in which female hormones are administered to alleviate symptoms caused by a lack of female hormones in menopausal women. When female hormones are administered alone, endometrial proliferation can occur, so progesterone is usually administered in combination.
그러나, 호르몬 대체요법의 경우, 5~10 년 이상 장기적으로 시행 시 암 (유방암, 자궁내막암 등) 발병 가능성에 대한 논쟁이 있고, 두통, 체중 증가 또는 심혈관 질환 발생 등의 부작용이 있으며, 인위적인 호르몬 투여에 대한 반감 및 월경 재개 가능성 등으로 인하여 많은 국내 여성들이 호르몬 요법에 대해 거부감을 가지고 있다. 이러한 점들을 고려해 볼 때, 여성 갱년기 증상에 대한 치료의 필요성은 느끼나, 갱년기 여성들의 상당수가 통원 치료나 투약에는 소극적일 것으로 추측된다. However, in the case of hormone replacement therapy, there is debate over the possibility of developing cancer (breast cancer, endometrial cancer, etc.) when administered over a long period of 5 to 10 years, and there are side effects such as headache, weight gain or cardiovascular disease, and artificial hormones. Due to the antipathy to administration and the possibility of menstruation resumption, many domestic women have a rejection of hormone therapy. Considering these points, the need for treatment for women's menopausal symptoms is felt, but it is estimated that a significant number of menopausal women will be passive in outpatient treatment or medication.
2018년 기준, 우리나라 여성의 평균수명이 84세임을 고려해 볼 때, 생애의 약 1/3 이상이 폐경 후의 삶이며, 대략 4백 50만명의 여성이 폐경기 여성에 해당하므로, 일반 갱년기 여성들을 대상으로 안전하고 복용이 편리한 여성 갱년기 증상을 개선할 수 있는 치료용 성분의 개발이 절실히 요구되고 있다.As of 2018, considering that the average life span of Korean women is 84 years old, more than a third of their lives are post-menopausal, and about 4.5 million women are menopausal women. There is an urgent need for the development of therapeutic ingredients that can improve the symptoms of menopause in women that are safe and convenient to take.
한편, 대부분의 갱년기 여성은 폐경 전 여성보다 허리둘레, 수축기 혈압, 맥압, 총 콜레스테롤, 저밀도 지단백 콜레스테롤 및 중성지방이 높다고 보고되고 있다. 특히, 갱년기 여성들은 여성 호르몬의 변화에 의해 대사적 변화가 많이 나타나는 시기이며, 특히 이 시기의 갱년기 여성들은 체지방이 증가하여 비만에 노출될 위험이 크다. 중년 여성들의 비만은 관상동맥, 심장질환, 뇌졸중, 당뇨병, 고혈압 등의 사망률을 증가시키는 성인병의 발병과 매우 관련이 높은 시기이다.Meanwhile, it is reported that most menopausal women have higher waist circumference, systolic blood pressure, pulse pressure, total cholesterol, low-density lipoprotein cholesterol, and triglycerides than premenopausal women. In particular, menopausal women are a time when many metabolic changes appear due to changes in female hormones, and in particular, menopausal women at this time are at increased risk of being exposed to obesity due to increased body fat. Obesity in middle-aged women is a time that is highly associated with the onset of adult diseases that increase mortality such as coronary artery, heart disease, stroke, diabetes, and high blood pressure.
이처럼 갱년기의 여성들은 각종 성인병 등의 발병과 관련이 높은 비만에 노출될 위험 또한 크며, 여성 갱년기 증상뿐만 아니라, 함께 동반되는 비만을 개선하기 위한 노력이 필요하다. As such, menopausal women are also at high risk of being exposed to obesity, which is highly related to the onset of various adult diseases, and efforts to improve not only female menopausal symptoms but also accompanying obesity are needed.
이러한 배경 하에, 본 발명의 발명자들은 여성 갱년기 증상 예방 또는 치료제를 연구하던 중, 동충하초 농축액이 여성 호르몬의 변화에 따라 발생하는 여성 갱년기 증상의 예방 또는 치료가 가능하며, 여성 갱년기에 의해 유도된 비만을 개선시키는 효과를 나타내어, 여성 갱년기 증상 및 여성 갱년기에 의해 유도된 비만의 예방 및 치료에 유용하게 사용할 수 있음을 확인하고 본 발명을 완성하였다.Under this background, the inventors of the present invention are researching the prevention or treatment of female menopausal symptoms, while cordyceps sinensis concentrate is capable of preventing or treating female menopausal symptoms caused by changes in female hormones, and obesity induced by female menopause. By showing the effect of improving, it was confirmed that it can be usefully used in the prevention and treatment of female menopausal symptoms and obesity induced by female menopause, and the present invention was completed.
본 발명의 목적은 동충하초(Cordyceps militaris) 농축액을 유효성분으로 포함하는 여성 갱년기 증상 예방 또는 치료용 약학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for preventing or treating female menopausal symptoms comprising a cordyceps militaris concentrate as an active ingredient.
본 발명의 다른 목적은 동충하초(Cordyceps militaris) 농축액을 유효성분으로 포함하는 여성 갱년기 증상 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing or improving female menopausal symptoms comprising a cordyceps militaris concentrate as an active ingredient.
본 발명자들은 여성 갱년기 증상의 예방 또는 치료에 대한 연구의 필요성을 인지하고 여성 갱년기 증상을 예방 또는 치료할 수 있는 천연 물질에 대한 연구의 목적을 달성하고자 하였다.The present inventors recognized the need for research on the prevention or treatment of female menopausal symptoms, and attempted to achieve the purpose of research on natural substances capable of preventing or treating female menopausal symptoms.
구체적으로, 본 발명의 발명자들은 여성 갱년기 증상에 대한 치료가 높은 성분을 탐색하던 중, 코디세핀(Cordycepin)을 함유하는 동충하초가 여성 갱년기 증상 및 여성 갱년기에 의해 유도된 비만을 개선하는 것을 발견하고 본 발명을 완성하게 되었다.Specifically, the inventors of the present invention discovered that cordycepin-containing cordyceps improves female menopausal symptoms and obesity induced by female menopause while searching for components with high treatment for female menopausal symptoms. The invention was completed.
본 발명에 따른 동충하초(Cordyceps militaris) 농축액은 여성 호르몬인 에스트로겐 활성이 있어 여성 호르몬 저감으로 인한 여성 갱년기 증상을 예방 또는 치료할 수 있음을 확인하였고, 또한, 여성 갱년기 유도 동물 모델에서 체중 증가 억제, 복부 지방 감량 및 혈중 지질 개선 효과가 있음을 확인함으로써, 동충하초(Cordyceps militaris) 농축액이 여성 갱년기에 의해 유도되는 비만을 억제하는 효과가 우수하다는 것을 확인하였다. Cordyceps militaris concentrate according to the present invention was confirmed to be able to prevent or treat female menopausal symptoms due to female hormone reduction due to the female hormone estrogen activity.In addition, in female menopausal induction animal models, weight gain inhibition, abdominal fat By confirming that there is an effect of reducing weight and improving blood lipids, it was confirmed that Cordyceps militaris concentrate has an excellent effect of inhibiting obesity induced by female menopause.
이하, 본 발명을 구체적으로 설명한다.Hereinafter, the present invention will be described in detail.
동충하초(Cordyceps sinensis ( Cordyceps militarisCordyceps militaris ) 농축액을 유효성분으로 포함하는 여성 갱년기 증상 예방 또는 치료용 약학적 조성물) Pharmaceutical composition for preventing or treating women's menopausal symptoms containing concentrate as an active ingredient
본 발명은 동충하초(Cordyceps militaris) 농축액을 유효성분으로 포함하는 여성 갱년기 증상 예방 또는 치료용 약학적 조성물을 제공한다. The present invention provides a pharmaceutical composition for preventing or treating female menopausal symptoms comprising a cordyceps militaris concentrate as an active ingredient.
최근 부작용이 없는 여성 갱년기 증상의 예방 또는 치료제에 대한 연구의 필요성이 지속적으로 대두되고 있다.Recently, the need for research on the prevention or treatment of women's menopausal symptoms without side effects has been continuously emerging.
구체적으로, 여성 갱년기 치료제로 에스트로겐을 투여하는 호르몬 대체요법이 가장 효과적인 방법으로 알려져 있으나, 장기간 약물을 사용하면 자궁내막암, 유방암, 고혈압, 혈전증, 당뇨계 결석 등을 일으킬 수 있으며, 출혈과 난소 과잉자극 등의 부작용으로 인하여 의사의 처방 없이는 복용할 수 없다는 문제점이 있다.Specifically, hormone replacement therapy in which estrogen is administered as a treatment for women's menopause is known to be the most effective method, but long-term use of drugs can cause endometrial cancer, breast cancer, high blood pressure, thrombosis, and diabetic stones, and bleeding and ovarian excess. There is a problem that it cannot be taken without a doctor's prescription due to side effects such as irritation.
그러나, 아직까지 여성 갱년기 증상에 효과적으로 예방 또는 치료 효과를 나타내는 천연 물질에 대한 연구가 미비한 실정이다. 본 발명자들은 연구가 전무한 동충하초 농축액을 활용해 여성 갱년기 증상의 예방 또는 치료 효과를 확인한 결과, 본 발명의 약학적 조성물은 천연 물질인 “동충하초 농축액”을 유효성분으로 포함하기 때문에, 에스트로겐 주입 시의 부작용이 나타나지 않으며, 여성 호르몬인 에스트로겐 활성이 있어 여성 호르몬 저감으로 인한 여성 갱년기 증상을 예방 또는 치료할 수 있으면서도 여성 갱년기 유도 동물 모델에서 체중 증가 억제, 복부 지방 감량 및 혈중 지질 개선 효과가 있음을 확인하였다.However, there is still insufficient research on natural substances that effectively prevent or treat women's menopausal symptoms. As a result of confirming the effect of preventing or treating female menopausal symptoms using cordyceps sinensis concentrate, which has not been studied, the present inventors have confirmed that the pharmaceutical composition of the present invention contains the natural substance "cordyceps sinensis concentrate" as an active ingredient, so the side effects of estrogen injection It was confirmed that the female hormone estrogen activity is capable of preventing or treating female menopausal symptoms caused by female hormone reduction, while suppressing weight gain, reducing abdominal fat, and improving blood lipids in female menopausal induction animal models.
본 명세서에 있어서, 용어 「동충하초(Cordyceps militaris)」는, 사상균의 일종으로 곤충에 기생하며, 숙주인 곤충을 죽이고 곤봉 모양 또는 줄 모양 등의 자실체를 낸다. 자실체는 머리·줄기의 2부분으로 이루어 지며, 머리부분은 공 모양, 양 끝이 뾰족한 원기둥 모양, 주걱 모양 등으로 불룩해지며, 그 표면 또는 표피 아래에 여러 개의 자낭각을 이룬다. 동충하초(Cordyceps militaris)는 한방에서는 약용버섯으로 이용되며, 약용버섯으로 한국, 일본, 중국, 네팔 등에 분포되어 있다. 동충하초(Cordyceps militaris)는 인삼, 녹용과 더불어 중국의 3대 보약 중의 하나로 불로장생 및 강장의 비약으로 알려져 있으며, 기능성 지표물질인 코디세핀이 다량 존재하고 면역력 증강, 노화억제, 피로회복과 같은 효능이 있는 것으로 보고 되어 있다. 또한, 동충하초(Cordyceps militaris) 농축액은 항염증 및 림프종, 백혈병, 방광암 등 항암활성과 면역력 조절 및 강화 효과가 있다고 보고되었다.In the present specification, the term "cordyceps militaris " is a type of filamentous fungus, which is parasitic to insects, kills the host insect, and produces fruiting bodies such as clubs or stripes. The fruiting body consists of two parts of a head and a stem, and the head is bulging into a ball shape, a cylinder shape with pointed ends, a spatula shape, etc., and forms several ascaris on the surface or under the epidermis. Cordyceps militaris is used as a medicinal mushroom in oriental medicine, and as a medicinal mushroom, it is distributed in Korea, Japan, China, and Nepal. Cordyceps militaris , along with ginseng and deer antlers, is known as one of the three major remedy in China, and is known as an elixir of longevity and tonic. It is reported to be. In addition, Cordyceps militaris concentrate has been reported to have anti-inflammatory and anti-cancer activities such as lymphoma, leukemia, and bladder cancer, as well as immunity control and strengthening effects.
본 명세서에 있어서, 용어 「농축액」은, 음용 가능한 액체로 희석되어 음료를 제공할 수 있거나 소비되기 전에 음식 제품에 첨가되는 액체 조성물을 지칭하는 것으로서, 천연물로부터 원료에 함유된 성분을 분리해낸 물질이라면, 농축 방법이나 성분의 종류와 무관하게 모두 포함할 수 있다. In the present specification, the term ``concentrate'' refers to a liquid composition that is diluted with a drinkable liquid to provide a beverage or is added to a food product before consumption, and if a substance obtained by separating the ingredients contained in the raw material from a natural product , Regardless of the method of concentration or the kind of ingredients, all can be included.
본 명세서에 있어서, 용어 「유효 성분」은 내재된 약리작용에 의해 그 조성물의 효능 효과를 직접 또는 간접적으로 발현한다고 기대되는 물질 또는 물질군(약리학적 활성성분 등이 밝혀지지 않은 생약 등을 포함한다)으로서 주성분을 포함하는 것을 의미한다.In the present specification, the term ``active ingredient'' includes a substance or group of substances that is expected to directly or indirectly express the efficacy effect of the composition through its inherent pharmacological action (including herbal medicines for which the pharmacologically active ingredient, etc. is not known. ) Means to include the main component.
본 명세서에 있어서, 용어 「여성 갱년기 증상」은, 노화에 따른 난소 기능 저화 및 여성 호르몬 저하로 인해 신체에 나타나는 모든 증상을 의미한다. 상기 여성 갱년기 증상은 주로, 혈중 지질 장애, 골밀도 감소, 체지방 증가, 복부 비만, 안면홍조, 발한, 피부건조, 질건조증, 질위축, 하부 요도 위축, 질 염, 방광염, 배뇨통, 급뇨, 집중장애, 단기 기억장애, 불안, 신경과민, 기억력 감퇴, 근육통, 관절통, 골다공증으로 나타날 수 있으나, 특히, 여성 갱년기 증상은 비만과 동반되는 체중 증가, 체지방 증가 및 복부 지방 증가를 의미한다.In the present specification, the term "female menopausal symptoms" refers to all symptoms that appear in the body due to ovarian function decline due to aging and female hormone decline. The female menopausal symptoms are mainly, blood lipid disorder, bone density decrease, body fat increase, abdominal obesity, facial flushing, sweating, skin dryness, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, urinary pain, urination, concentration disorder, Short-term memory impairment, anxiety, nervousness, memory loss, muscle pain, joint pain, and osteoporosis may appear. In particular, women's menopausal symptoms mean weight gain, body fat increase, and abdominal fat increase associated with obesity.
본 명세서에 있어서, 용어 「예방」은, 본 발명에 따른 약학적 조성물의 투여로 여성 갱년기 증상을 억제 또는 지연시키는 모든 행위를 말한다.In the present specification, the term "prevention" refers to all actions of suppressing or delaying female menopausal symptoms by administration of the pharmaceutical composition according to the present invention.
본 명세서에 있어서, 용어 「치료」는, 본 발명에 따른 약학적 조성물의 투여로 여성 갱년기때 나타나는 증상이 호전되거나 이롭게 변경하는 모든 행위를 말한다.In the present specification, the term "treatment" refers to any action in which symptoms appearing during female menopause are improved or beneficially changed by administration of the pharmaceutical composition according to the present invention.
본 발명의 일 구현예에 있어서, 상기 동충하초(Cordyceps militaris) 추출물은 물, 탄소수 1 내지 4의 무수 저급 알코올 또는 탄소수 1 내지 4의 함수 저급 알코올 용매 하에 추출하여 제조될 수 있다.In one embodiment of the present invention, the Cordyceps militaris extract may be prepared by extraction in water, an anhydrous lower alcohol having 1 to 4 carbon atoms, or a hydrated lower alcohol solvent having 1 to 4 carbon atoms.
본 명세서에 있어서, 용어 「탄소수 1 내지 4의 무수 저급 알코올」은, 물을 함유하지 않은 저급 알코올로써, 예컨대 메탄올, 에탄올, 프로판올, 부탄올, 이소부탄올을 포함하나, 이에 제한되지 않는다. 또한, 용어 「탄소수 1 내지 4의 함수 저급 알코올」은, 물과 혼합된 저급 알코올로 예컨대 메탄올, 에탄올, 프로판올, 부탄올, 이소부탄올과 물의 혼합용매이며, 구체적으로는 물과 에탄올의 혼합용매일 수 있고, 이때 물과 에탄올의 혼합 비율은 물과 에탄올을 7 : 3 내지 3 : 7 부피 비율로 혼합한 30%(v/v) 내지 70%(v/v) 에탄올 수용액일 수 있고, 구체적으로는 물과 에탄올을 5 : 5 부피 비율로 혼합한 50%(v/v) 에탄올 수용액 일 수 있다.In the present specification, the term "anhydrous lower alcohol having 1 to 4 carbon atoms" is a lower alcohol that does not contain water, and includes, for example, methanol, ethanol, propanol, butanol, and isobutanol, but is not limited thereto. In addition, the term ``hydrous lower alcohol having 1 to 4 carbon atoms'' is a lower alcohol mixed with water, for example, methanol, ethanol, propanol, butanol, isobutanol, and a mixed solvent of water, and specifically, may be a mixed solvent of water and ethanol. In this case, the mixing ratio of water and ethanol may be 30% (v/v) to 70% (v/v) ethanol aqueous solution obtained by mixing water and ethanol in a volume ratio of 7:3 to 3:7, and specifically It may be a 50% (v/v) aqueous ethanol solution in which water and ethanol are mixed in a volume ratio of 5:5.
본 발명의 일 구현예에 있어서, 상기 동충하초(Cordyceps militaris) 농축액은 코디세핀(codycepin)을 함유하며, 상기 코디세핀(codycepin)의 함량은 동충하초(Cordyceps militaris) 농축액 총 중량에 대해 0.02 내지 10 중량%일 수 있고, 구체적으로는 0.1 내지 5 중량%이거나, 0.2 내지 2 중량%의 높은 함량으로 함유할 수 있다.In one embodiment of the present invention, the cordyceps militaris concentrate contains cordycepin, and the content of cordycepin is 0.02 to 10% by weight based on the total weight of the cordyceps militaris concentrate. It may be, specifically 0.1 to 5% by weight, or may be contained in a high content of 0.2 to 2% by weight.
본 명세서에 있어서, 용어 「코디세핀(codycepin)」은, 동충하초에 함유된 항세균, 항진균, 항바이러스 효과, 혈소판응집 억제 효과 및 면역증강을 통한 항암 효과 등이 알려진 생리활성물질 중 하나로, 3-deoxyadenosine 계통의 천연화합물이다.In the present specification, the term ``codycepin'' is one of known physiologically active substances such as antibacterial, antifungal, antiviral effect, platelet aggregation inhibitory effect, and anticancer effect through immunity contained in Cordyceps sinensis, 3- It is a natural compound of the deoxyadenosine family.
본 발명의 일 구현예에 있어서, 상기 여성 갱년기 증상은 여성 호르몬 감소로 인한 것일 수 있다.In one embodiment of the present invention, the female menopausal symptoms may be due to a decrease in female hormones.
본 명세서에 있어서, 용어 「여성 호르몬」은, 난소에서 분비되는 호르몬으로, 난포호르몬(FSH)인 에스트로겐(estrogen)과 황체호르몬(LH)인 프로게스테론(progesteron)을 의미할 수 있으며, 구체적으로 에스트로겐을 의미한다.In the present specification, the term ``female hormone'' is a hormone secreted by the ovary, and may mean estrogen, which is follicular hormone (FSH), and progesteron, which is a progesterone (LH), and specifically estrogen. it means.
본 발명의 일 구현예에 있어서, 상기 여성 갱년기 증상은 혈중 지질 장애, 골밀도 감소, 체지방 증가, 복부 비만, 안면홍조, 발한, 피부건조, 질건조증, 질위축, 하부 요도 위축, 질 염, 방광염, 배뇨통, 급뇨, 집중장애, 단기 기억장애, 불안, 신경과민, 기억력 감퇴, 근육통, 관절통, 골다공증 또는 그의 조합일 수 있다.In one embodiment of the present invention, the female menopausal symptoms include blood lipid disorder, bone density decrease, body fat increase, abdominal obesity, hot flashes, sweating, skin dryness, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, It may be urinary pain, urination, concentration disorder, short-term memory impairment, anxiety, nervousness, memory loss, muscle pain, joint pain, osteoporosis, or a combination thereof.
본 발명의 일 구현예에 있어서, 상기 동충하초(Cordyceps militaris) 농축액은 (S1) 동충하초(Cordyceps militaris)와 제1 추출 용매를 혼합하고 추출하여 1차 추출액을 수득하는 제1차 추출 단계 및 상기 제1차 추출 단계를 거친 동충하초(Cordyceps militaris) 고형물과 제2 추출 용매를 혼합하고 추출하여 2차 추출액을 수득하는 제2차 추출 단계에 의해 수득될 수 있다.In one embodiment of the present invention, the cordyceps militaris concentrate is a first extraction step of obtaining a first extract by mixing and extracting (S1) Cordyceps militaris and a first extraction solvent, and the first It can be obtained by a second extraction step of mixing and extracting the Cordyceps militaris solids subjected to the tea extraction step and a second extraction solvent to obtain a second extract.
상기 제1 추출 용매는 동충하초(Cordyceps militaris)를 세척하여 이물질을 제거하고, 건조를 통해 수분을 제거한 후, 건조된 동충하초(Cordyceps militaris)와 혼합되는 추출 용매를 의미한다. 상기 제1 추출 용매는 물, 탄소수 1 내지 4의 무수 저급 알코올 또는 탄소수 1 내지 4의 함수 저급 알코올 용매일 수 있으며, 상기 기재된 내용과 동일하게 적용이 가능하다.The first extraction solvent refers to an extraction solvent that is mixed with the dried Cordyceps militaris after removing foreign substances by washing the Cordyceps militaris , removing moisture through drying, and drying the cordyceps militaris . The first extraction solvent may be water, an anhydrous lower alcohol having 1 to 4 carbon atoms, or a hydrated lower alcohol solvent having 1 to 4 carbon atoms, and can be applied in the same manner as described above.
상기 제1차 추출 단계는 건조된 동충하초(Cordyceps militaris)와 제1 추출 용매를 혼합하는 것으로, 동충하초(Cordyceps militaris)의 kg당 5L 내지 20L의 제1 추출 용매가 혼합될 수 있으며, 구체적으로는 동충하초(Cordyceps militaris) 20 kg에는 50L 내지 400L의 제1 추출 용매가 혼합될 수 있고, 구체적으로는 동충하초(Cordyceps militaris) 20 kg에는 100L 내지 300L의 제1 추출 용매가 혼합될 수 있으며, 이에 한정되는 것은 아니다. 상기 제1차 추출 단계는 동충하초(Cordyceps militaris)와 제1 추출 용매가 혼합된 상태로 24 시간 내지 120 시간 동안 추출할 수 있고, 구체적으로는 48 시간 내지 96 시간 동안 추출할 수 있으며, 이에 한정되는 것은 아니다. The first extraction step is to mix the dried cordyceps militaris and the first extraction solvent, 5L to 20L of the first extraction solvent per kg of Cordyceps militaris may be mixed, specifically Cordyceps militaris ( Cordyceps militaris ) 20 kg of 50L to 400L of the first extraction solvent may be mixed, specifically, Cordyceps militaris 20 kg of 100L to 300L of the first extraction solvent may be mixed, and limited thereto no. The first extraction step may be extracted for 24 to 120 hours in a state in which Cordyceps militaris and the first extraction solvent are mixed, and specifically, may be extracted for 48 to 96 hours, and is limited thereto. It is not.
상기 1차 추출액은 상기 제1차 추출 단계를 거치고 분리된 액상의 용액을의미한다. The first extraction liquid refers to a liquid solution separated after the first extraction step.
상기 제2 추출 용매는 상기 제1차 추출 단계를 거친 고상의 동충하초(Cordyceps militaris) 고형물과 혼합되는 추출 용매를 의미한다. 상기 제2 추출 용매는 물, 탄소수 1 내지 4의 무수 저급 알코올 또는 탄소수 1 내지 4의 함수 저급 알코올 용매일 수 있으며, 상기 기재된 내용과 동일하게 적용이 가능하다.The second extraction solvent means an extraction solvent mixed with the solid Cordyceps militaris solid that has been subjected to the first extraction step. The second extraction solvent may be water, an anhydrous lower alcohol having 1 to 4 carbon atoms, or a hydrated lower alcohol solvent having 1 to 4 carbon atoms, and can be applied in the same manner as described above.
상기 제2차 추출 단계는 상기 제1차 추출 단계를 거친 고상의 동충하초(Cordyceps militaris) 고형물과 제2 추출 용매를 혼합하는 것으로, 동충하초(Cordyceps militaris)의 kg당 1L 내지 4L의 제2 추출 용매가 혼합될 수 있고, 구체적으로 동충하초(Cordyceps militaris) 20 kg에는 20L 내지 80L의 제2 추출 용매가 혼합될 수 있으며, 이에 한정되는 것은 아니다. 상기 제2차 추출 단계는 동충하초(Cordyceps militaris) 고형물과 제2 추출 용매가 혼합된 상태로 1 시간 내지 10 시간 동안 추출할 수 있고, 구체적으로는 2 시간 내지 6 시간 동안 추출할 수 있으며, 이에 한정되는 것은 아니다.The second extraction step is to mix the solid cordyceps militaris solid material and the second extraction solvent that has been subjected to the first extraction step, and 1L to 4L of the second extraction solvent per kg of Cordyceps militaris is It may be mixed, specifically Cordyceps militaris 20 kg of the second extraction solvent of 20L to 80L may be mixed, but is not limited thereto. The second extraction step may be extracted for 1 to 10 hours in a state in which the Cordyceps militaris solid and the second extraction solvent are mixed, and specifically for 2 to 6 hours, limited thereto. It does not become.
상기 2차 추출액은 제2차 추출 단계를 거치고 분리된 액상의 용액을 의미한다.The second extract refers to a liquid solution separated after a second extraction step.
본 발명에 따른 조성물의 동충하초(Cordyceps militaris) 농축액을 추출하는 방법은 열수 추출, 침지 추출, 초음파 추출, 진탕 추출, 속실렛(Soxhelt) 추출 또는 환류 추출을 이용할 수 있으며, 구체적으로는 물과 에탄올 혼합한 50% 에탄올을 이용한 진탕 추출일 수 있고, 이에 한정되지 않는다. 추출 횟수는 1회 내지 5회 일 수 있고, 구체적으로는 1회 내지 3회 일 수 있으며 이에 한정되는 것은 아니다. 추출 시간은 1 시간 내지 120 시간일 수 있고, 구체적으로는 3 시간 내지 96 시간 동안 추출을 수행할 수 있으며, 이에 한정되는 것은 아니다. 또한, 추출 온도는 20℃ 내지 40℃일 수 있고, 구체적으로는 25℃ 내지 35℃일 수 있으며, 이에 한정되는 것은 아니다. The method of extracting the concentrate of Cordyceps militaris of the composition according to the present invention may use hot water extraction, immersion extraction, ultrasonic extraction, shaking extraction, Soxhelt extraction, or reflux extraction, specifically mixing water and ethanol It may be shaking extraction using 50% ethanol, but is not limited thereto. The number of extractions may be 1 to 5 times, specifically 1 to 3 times, but is not limited thereto. The extraction time may be 1 hour to 120 hours, specifically, extraction may be performed for 3 hours to 96 hours, but is not limited thereto. In addition, the extraction temperature may be 20°C to 40°C, specifically 25°C to 35°C, but is not limited thereto.
상기 추출 용매의 양은 동충하초(Cordyceps militaris) 건조 중량의 1 내지 20 배로 한다. 상기 동충하초(Cordyceps militaris) 농축액은 동충하초(Cordyceps militaris) 농축액을 포함하는 조성물의 총 중량에 대하여 0.1 중량% 내지 95 중량%의 함량을 가진다. The amount of the extraction solvent is 1 to 20 times the dry weight of Cordyceps militaris . The cordyceps militaris concentrate has a content of 0.1% to 95% by weight based on the total weight of the composition comprising the cordyceps militaris concentrate.
본 발명에 따른 동충하초(Cordyceps militaris) 농축액은 하기 단계를 더 포함하여 수득하는 것일 수 있으며, 이에 한정되는 것은 아니다. Cordyceps militaris according to the present invention may be obtained by further comprising the following steps, but is not limited thereto.
본 발명의 일 구현예에 있어서, 상기 동충하초(Cordyceps militaris) 농축액은 상기 제1차 추출 단계 및 제2차 추출 단계 이후에 (S2) 상기 1차 추출액 및 상기 2차 추출액을 규조토 여과보조제를 사용하여 감압 여과하여 여과액을 수득하는 여과 단계 및 (S3) 상기 여과액을 감압 농축하여 동충하초(Cordyceps militaris) 농축액을 수득하는 농축 단계로 수득될 수 있다.In one embodiment of the present invention, the cordyceps militaris concentrate is (S2) the first extract and the second extract using a diatomaceous earth filter aid after the first extraction step and the second extraction step. It can be obtained by a filtration step of filtration under reduced pressure to obtain a filtrate, and (S3) a concentration step of obtaining a concentrate of Cordyceps militaris by concentrating the filtrate under reduced pressure.
상기 여과는 당업계의 통상의 방법에 따라 용액을 여과하거나 원심분리를 통해 여액 또는 상등액을 수득할 수 있다. 상기 농축은 바람직하게 감압 농축이며, 감압 농축은 진공 감압 농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정되지 않는다. 이러한 농축에 의해 액상 또는 분말 형태로 동충하초 농축액을 추출한다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조하는 것이 바람직하나 이에 한정되지 않는다.In the filtration, the solution may be filtered or centrifuged according to a conventional method in the art to obtain a filtrate or a supernatant. The concentration is preferably concentrated under reduced pressure, and the concentration under reduced pressure is preferably a vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto. Cordyceps sinensis concentrate is extracted in liquid or powder form by this concentration. In addition, the drying is preferably vacuum drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.
본 발명의 약학적 조성물은 동충하초(Cordyceps militaris) 농축액을 유효성분으로 함유하고, 약학적으로 허용가능한 담체를 추가로 포함할 수 있으며, 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 및 멸균 주사용액의 형태로 제제화될 수 있다. The pharmaceutical composition of the present invention contains a concentrate of Cordyceps militaris as an active ingredient, and may further include a pharmaceutically acceptable carrier, and powders, granules, tablets, capsules, suspensions, according to conventional methods, It can be formulated in the form of oral dosage forms such as emulsions, syrups, aerosols, external preparations, and sterile injectable solutions.
본 명세서에 있어서, 용어 「약학적으로 허용 가능한」은, 생리학적으로 허용되고 인간에게 투여될 때, 통상적으로 위장 장애, 현기증 등과 같은 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 조성물을 말한다.In the present specification, the term "pharmaceutically acceptable" refers to a composition that is physiologically acceptable and does not usually cause allergic reactions such as gastrointestinal disorders and dizziness or similar reactions when administered to humans.
본 명세서에 있어서, 용어 「약학적으로 허용 가능한 담체」는, 전형적으로 약학적 조성물의 액체 또는 비액체 기초를 포함한다. 만약 약학적 조성물이 액체 형태로 제공된다면, 담체는 전형적으로 피로겐 없는 물; 등장성 식염수 또는 버퍼(수용성) 용액, 예를 들어 인산염, 구연산 등 버퍼 용액이다. 주사 버퍼는 특정한 기준 매질(Reference media)에 고장성, 등장성 또는 저장성 기준일 수 있어, 즉 버퍼는 특정한 기준 매질에 높은, 같은 또는 낮은 염 함량을 가질 수 있으며, 바람직하게는, 삼투압 또는 다른 농도 효과에 의한 세포 손상을 유도하지 않는, 앞서 언급된 염의 상기 이러한 농도가 사용될 수 있다. 기준 매질은 혈액, 림프, 세포질 액상, 또는 다른 체액, 또는 예를 들어 일반적인 버퍼 또는 액체로써 "생체 외" 방법에 기준 매질로 사용될 수 있는 체액과 같은, 예를 들어 "생체 내" 방법에서 발생하는 액체이다. 이러한 일반적 버퍼 또는 액체는 통상의 기술자에게 알려져 있다.In the present specification, the term "pharmaceutically acceptable carrier" typically includes a liquid or non-liquid basis of a pharmaceutical composition. If the pharmaceutical composition is provided in liquid form, the carrier typically comprises pyrogen-free water; Isotonic saline or buffer (aqueous) solutions such as phosphate, citric acid, etc. buffer solutions. The injection buffer can be on a hypertonic, isotonic or hypotonic basis for a specific reference media, i.e. the buffer can have a high, the same or a low salt content for a specific reference media, preferably osmotic pressure or other concentration effects. Such concentrations of the aforementioned salts, which do not induce cell damage by, can be used. The reference medium is blood, lymph, cytoplasmic liquid, or other body fluid, or a body fluid that can be used as a reference medium in the "ex vivo" method, for example as a general buffer or liquid. It is liquid. Such general buffers or liquids are known to the skilled person.
상기 약학적으로 허용가능한 담체는 당업계에서 통상적으로 사용되는 것들, 예컨대 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함하나 이에 국한되지 않는다. The pharmaceutically acceptable carriers are those commonly used in the art, such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, but are not limited thereto.
또한, 본 발명의 약제학적 조성물은 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제, 기타 약제학적으로 허용가능한 첨가제를 포함할 수 있다. In addition, the pharmaceutical composition of the present invention may contain diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and other pharmaceutically acceptable additives.
본 발명의 약학적 조성물은 액상제, 현탁제, 산제, 과립제, 정제, 캡슐제, 환제 또는 엑스제의 형태로 제조될 수 있다. The pharmaceutical composition of the present invention may be prepared in the form of a liquid, suspension, powder, granule, tablet, capsule, pill, or extract.
본 발명의 조성물은 경구 또는 비경구 투여(예를 들어, 도포 또는 정맥 내, 피하, 복강 내 주사)할 수 있다.The composition of the present invention can be administered orally or parenterally (eg, application or intravenous, subcutaneous, intraperitoneal injection).
본 명세서에 있어서, 용어 「경구 투여」는 병리학적 증상을 호전하기 위한 약제를 입으로 주입하는 방법이며, 본 명세서에 있어서, 용어 「비경구투여」는 입으로 투여하는 것을 제외한 피하, 근육내, 정맥, 튜브를 이용한 복강내로 투여하는 방법을 의미한다.In the present specification, the term "oral administration" is a method of injecting a drug for improving pathological symptoms by mouth, and in the present specification, the term "parenteral administration" refers to subcutaneous, intramuscular, and It refers to a method of intraperitoneal administration using an intravenous or tube.
경구 투여를 위한 고형제제에는 산제, 과립제, 정제, 캡슐제, 연질캡슐제, 환제 등이 포함된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액상제, 유제, 시럽제, 에어로졸 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. Solid preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills, and the like. Liquid preparations for oral administration include suspensions, liquid contents, emulsions, syrups, aerosols, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as humectants, sweeteners, fragrances, preservatives, etc. May be included.
비경구 투여를 위한 제제로는 각각 통상의 방법에 따라 멸균된 수용액, 액상제, 비수성용제, 현탁제, 에멀젼, 점안제, 안연고제, 시럽, 좌제, 에어로졸 등의 외용제 및 멸균 주사제제의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 안연고제, 점안제, 파스타제 또는 카타플 라스마제의 약제학적 조성물을 제조하여 사용할 수 있으나, 이에 한정되는 것은 아니다. 국소 투여의 조성물은 임상적 처방에 따라 무수형 또는 수성형일 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include aqueous solutions, liquids, non-aqueous solutions, suspensions, emulsions, eye drops, ointments, syrups, suppositories, aerosols, and other external preparations and sterile injections, each sterilized according to a conventional method. It may be used in combination, and preferably, a pharmaceutical composition of cream, gel, patch, spray, ointment, warning agent, lotion, liniment, eye ointment, eye drop, pasta or cataplasma may be prepared and used. However, it is not limited thereto. Compositions for topical administration may be anhydrous or aqueous, depending on the clinical prescription. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like may be used.
본 발명에 따른 약제학적으로 허용가능한 첨가제는 상기 조성물에 대해 0.1~99.9 중량부 포함될 수 있으며, 구체적으로는 0.1~50 중량부를 포함할 수 있고, 이에 제한되는 것은 아니다.The pharmaceutically acceptable additive according to the present invention may include 0.1 to 99.9 parts by weight, specifically 0.1 to 50 parts by weight, with respect to the composition, but is not limited thereto.
본 발명의 조성물의 바람직한 투여량은 체내에서 활성성분의 흡수도, 환자의 연령, 성별 및 비만의 정도에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 경구 투여제의 경우 일반적으로 성인에게 1일에 체중 1 ㎏당 본 발명의 조성물을 1일 0.0001 내지 40 ㎎/㎏으로, 바람직하게는 0.001 내지 20 ㎎/㎏으로 투여하는 것이 좋다.The preferred dosage of the composition of the present invention depends on the degree of absorption of the active ingredient in the body, the age, sex, and degree of obesity of the patient, but may be appropriately selected by those skilled in the art. However, for a desirable effect, in the case of oral administration, the composition of the present invention per 1 kg of body weight per day is generally administered to an adult at 0.0001 to 40 mg/kg per day, preferably 0.001 to 20 mg/kg. It is good.
투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Administration may be administered once a day, or may be divided several times. The above dosage does not in any way limit the scope of the present invention.
본 발명의 여성 갱년기 증상 예방 또는 치료용 조성물은 동충하초(Cordyceps militaris) 농축액에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.The composition for preventing or treating female menopausal symptoms of the present invention may contain one or more active ingredients showing the same or similar function in addition to the concentrate of Cordyceps militaris .
동충하초(Cordyceps sinensis ( Cordyceps militarisCordyceps militaris ) 농축액을 유효성분으로 포함하는 여성 갱년기 증상 예방 또는 개선용 식품 조성물) Food composition for preventing or improving women's menopausal symptoms containing concentrate as an active ingredient
본 발명은 동충하초(Cordyceps militaris) 농축액을 유효성분으로 포함하는 여성 갱년기 증상 예방 또는 개선용 식품 조성물을 제공한다.The present invention provides a food composition for preventing or improving women's menopausal symptoms comprising a cordyceps militaris concentrate as an active ingredient.
본 발명에 따른 여성 갱년기 증상 예방 또는 개선용 식품 조성물은 체중감소 억제 효과, 에스트로겐 수용체 활성화 등을 통해서 여성 갱년기 증상 예방 또는 치료에 우수한 효과를 보인다. 또한, 경구 투여를 통해서도 우수한 작용 효과를 보여 복약 순응도가 매우 높다.The food composition for preventing or improving female menopausal symptoms according to the present invention exhibits excellent effects in preventing or treating female menopausal symptoms through weight loss inhibitory effect and estrogen receptor activation. In addition, it shows an excellent effect even through oral administration, so the medication compliance is very high.
본 명세서에 있어서, 용어 「개선」은, 본 발명에 따른 동충하초(Cordyceps militaris) 농축액을 포함하는 약학적 조성물을 투여하거나 섭취하여 여성 갱년기에 나타나는 모든 나쁜 상태를 좋게 하는 행위를 의미한다.In the present specification, the term "improvement" refers to the act of improving all bad conditions that appear in female menopause by administering or ingesting a pharmaceutical composition containing the concentrate of Cordyceps militaris according to the present invention.
본 발명의 식품 조성물은 건강 기능 식품으로서 사용될 수 있다. 본 명세서에서 용어 「건강 기능 식품」 이라 함은, 건강 기능 식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, 본 명세서에서 용어 「인체에 유용한 기능성」이라 함은, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.The food composition of the present invention can be used as a health functional food. In the present specification, the term "health functional food" refers to a food manufactured and processed using raw materials or ingredients having functions useful for the human body according to the Health Functional Food Act No.6727, and in this specification, the term " "Functionality useful for the human body" means ingestion for the purpose of obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.
본 발명의 동충하초(Cordyceps militaris) 농축액을 건강 기능 식품 또는 건강 기능 음료 첨가물로 사용할 경우, 상기 동충하초(Cordyceps militaris) 농축액을 그대로 첨가하거나 통상의 식품 첨가물과 함께 사용되고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안정청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. 상기 “식품 첨가물 공전”에 기재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류들을 들 수 있다. 상기 동충하초(Cordyceps militaris) 농축액의 혼합량은 그의 사용목적(예방, 건강 또는 개선, 치료적 처치)에 따라 적합하게 결정될 수 있다. 건강 및 위생을 목적으로 하거나 또는 건강조절을 목적으로 하는 장기간의 섭취의 경우, 상기 동충하초(Cordyceps militaris) 농축액은 안전성 면에서 아무런 문제가 없기 때문에, 장기간 복용이 가능하다. When using the cordyceps militaris concentrate of the present invention as a health functional food or health functional beverage additive, the cordyceps militaris concentrate is added as it is or used with a conventional food additive, and can be appropriately used according to a conventional method. have. Unless otherwise specified, the suitability as a food additive shall be determined according to the standards and standards for the relevant item in accordance with the General Regulations of Food Additives Code and General Test Methods approved by the Food and Drug Administration. Items described in the above "Food Additives Code" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as dark pigments, licorice extract, crystalline cellulose, high color pigments, and guar gum, L -Mixed preparations such as sodium glutamate preparations, noodle-added alkali preparations, preservatives preparations, and tar coloring preparations. The mixed amount of the cordyceps militaris concentrate may be appropriately determined according to the purpose of use (prevention, health or improvement, therapeutic treatment). In the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the Cordyceps militaris concentrate has no problem in terms of safety, and thus can be taken for a long time.
본 발명의 식품 조성물은 식품 및 음료 등에 다양하게 이용될 수 있으며, 종류에는 특별한 제한은 없다. 상기 동충하초(Cordyceps militaris) 농축액을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿류, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등에 사용될 수 있고, 분말, 과립, 정제, 캡슐, 환 또는 음료인 형태로 사용할 수 있다. 상기 기재한 것 외에도 모든 식품 형태일 수 있다.The food composition of the present invention may be variously used for foods and beverages, and there is no particular limitation on the type. Examples of foods to which the Cordyceps militaris concentrate can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, It can be used for beverages, teas, drinks, alcoholic beverages and vitamin complexes, and can be used in the form of powders, granules, tablets, capsules, pills or beverages. In addition to those described above, it can be in any food form.
음료수로 제형화할 경우에 동충하초(Cordyceps militaris) 농축액 이외에 첨가되는 액체 성분으로는 이에 한정되지는 않으나, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드(예, 포도당, 과당 등), 디사카라이드(예, 말토오스, 수크로오스 등) 및 폴리사카라이드(예, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당), 및 자일리톨, 소르비톨, 에리스리톨 등의 당 알코올이다. 이외에도 감미제로서 천연 감미제[타우마린, 스테비아 추출물(예, 레바우디오시드 A, 글리시르히진 등)] 및 합성 감미제(예, 사카린, 아스파르탐 등)를 사용할 수 있다.When formulated as a beverage, the liquid component added in addition to the Cordyceps militaris concentrate is not limited thereto, but may contain various flavoring agents or natural carbohydrates as an additional component, such as a conventional beverage. Examples of the natural carbohydrates described above are monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.) and polysaccharides (e.g., common sugars such as dextrin, cyclodextrin, etc.), and xylitol. , Sorbitol, and sugar alcohols such as erythritol. In addition, natural sweeteners [taumarin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)] and synthetic sweeteners (eg, saccharin, aspartame, etc.) may be used as sweetening agents.
다른 실시양태로서, 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 증진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 유기산, 보호성 콜로이드 점증제, pH 조절제, 안정화제, 보존제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 또한 본 발명의 식품 조성물은 과일 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 단독으로 또는 조합으로 사용될 수 있으며, 이러한 첨가제의 비율은 조성물 전체 중량당 0.001 내지 50 중량부의 범위에서 선택되는 것이 일반적이다.In another embodiment, the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and enhancing agents (cheese, chocolate, etc.), pectic acid and salts thereof, Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like may be contained. In addition, the food composition of the present invention may contain pulp for the production of fruit and vegetable beverages. These components may be used alone or in combination, and the proportion of these additives is generally selected from 0.001 to 50 parts by weight per total weight of the composition.
다른 실시양태로서, 본 발명의 동충하초(Cordyceps militaris) 농축액이 포함된 제품은 분말, 과립, 정제, 캡슐, 시럽제 또는 음료일 수 있다.In another embodiment, the product containing the concentrate of Cordyceps militaris of the present invention may be a powder, granule, tablet, capsule, syrup, or beverage.
여성 갱년기 증상의 예방, 개선 또는 치료방법How to prevent, ameliorate or treat women's menopausal symptoms
본 발명은 치료학적으로 유효한 양의 동충하초(Cordyceps militaris) 농축액을 치료가 필요한 대상체에게 투여하여 여성 갱년기 증상을 예방, 개선 또는 치료하는 방법을 제공한다. 본 명세서에서 용어 「치료가 필요한 대상체」는, 인간을 위시한 포유동물을 의미하고, 용어 「투여」는 임의의 적절한 방법으로 환자에게 소정의 물질을 제공하는 것을 의미한다. 용어 「치료학적으로 유효한 양」은 연구자, 수의사, 의사 또는 기타 임상의에 의해 생각되는 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 활성 성분 또는 약학적 조성물의 양을 의미하는 것으로, 이는 치료되는 질환 또는 장애의 증상 완화를 유도하는 양을 포함한다. 본 발명의 유효 성분에 대한 치료상 유효 투여량 및 투여횟수는 원하는 효과에 따라 변화될 것임은 당업자에게 자명하다.The present invention provides a method for preventing, improving or treating female menopausal symptoms by administering a therapeutically effective amount of Cordyceps militaris concentrate to a subject in need of treatment. In the present specification, the term "subject in need of treatment" refers to a mammal, including humans, and the term "administration" refers to providing a predetermined substance to a patient by any suitable method. The term ``therapeutically effective amount'' refers to the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in an animal or human considered by a researcher, veterinarian, doctor or other clinician, which is a disease to be treated. Or an amount that induces symptomatic relief of the disorder. It is obvious to those skilled in the art that the therapeutically effective dosage and frequency of administration of the active ingredient of the present invention will vary depending on the desired effect.
여성 갱년기 증상의 치료를 위한 약제학적 제제를 제조하는 데 상기 동충하초(In the manufacture of a pharmaceutical formulation for the treatment of female menopausal symptoms, the cordyceps sinensis ( Cordyceps militarisCordyceps militaris ) 농축액을 사용하는 용도) Use of concentrate
본 발명은 여성 갱년기 증상의 치료를 위한 약제학적 제제를 제조하는 데 상기 동충하초(Cordyceps militaris) 농축액을 사용하는 용도를 제공한다. 본 발명의 용도는 여성 갱년기 증상을 에방, 개선 또는 치료하여 여성 갱년기 증상의 치료를 위한 약제학적 제제를 제조하는 데 이용될 수 있다.The present invention provides a use of the cordyceps militaris concentrate to prepare a pharmaceutical formulation for the treatment of female menopausal symptoms. The use of the present invention can be used to prevent, ameliorate or treat female menopausal symptoms to prepare a pharmaceutical formulation for the treatment of female menopausal symptoms.
본 발명의 약학적 조성물, 식품 조성물, 치료방법 및 용도에서 언급된 사항은 서로 모순되지 않는 한 동일하게 적용된다.The matters mentioned in the pharmaceutical composition, food composition, treatment method and use of the present invention apply equally unless contradictory to each other.
본 발명의 동충하초(Cordyceps militaris) 농축액은 에스트로겐 활성이 입증되고, 여성 갱년기 유도 동물 모델에서 여성 갱년기에 의해 유도된 체중 증가, 식이 증가, 체지방 및 복부 지방을 감소하여, 여성 갱년기 증상 및 여성 갱년기 증상과 동반되는 비만을 예방 또는 개선에 우수한 효과가 있다. Cordyceps militaris concentrate of the present invention has proven estrogen activity, and reduced weight gain, diet increase, body fat and abdominal fat induced by female menopause in a female menopausal induction animal model, thereby reducing female menopausal symptoms and female menopausal symptoms. It has an excellent effect in preventing or improving accompanying obesity.
도 1은 본 발명의 일 실시예에 따른, 동충하초(Cordyceps militaris) 농축액을 에스트로겐 자극으로 증식하는 MCF-7 세포에 처리함에 따라 세포 증식 여부를 확인함으로써, 에스트로겐 유사 활성을 확인한 그래프이다.
도 2는 퀸즈원정(Queens One Tab)을 에스트로겐 자극으로 증식하는 MCF-7 세포에 처리함에 따라 세포 증식 여부를 확인함으로써 에스트로겐 유사 활성을 확인한 그래프이다.
도 3은 본 발명의 일 실시예에 따른, 동충하초(Cordyceps militaris) 농축액의 에스트로겐 수용체 반응을 확인하기 위한, ERα 및 인산화 ERα(pERα)의 발현을 측정한 웨스턴 블럿 결과를 나타내는 도이다.
도 4는 본 발명의 일 실시예에 따른, 여성 갱년기 증상 유도 동물 모델에서 동충하초(Cordyceps militaris) 농축액의 체중 감소 효과를 나타내는 그래프이다.
도 5는 본 발명의 일 실시예에 따른, 여성 갱년기 증상 유도 동물 모델에서 동충하초(Cordyceps militaris) 농축액의 식이 섭취 변화를 나타내는 그래프이다.
도 6은 본 발명의 일 실시예에 따른, 여성 갱년기 증상 유도 동물 모델에서 동충하초(Cordyceps militaris) 농축액의 지방 함량(%) 변화를 나타내는 그래프이다.
도 7은 본 발명의 일 실시예에 따른, 여성 갱년기 증상 유도 동물 모델에서 동충하초(Cordyceps militaris) 농축액의 전신을 이중 에너지 X-선 흡수법(dual energy X-ray absorptiometry)으로 촬영한 사진으로 파랑, 노랑, 빨강 순서로 저밀도, 중밀도, 고밀도 지방을 의미한다.
도 8은 본 발명의 일 실시예에 따른, 여성 갱년기 증상 유도 동물 모델에서 동충하초(Cordyceps militaris) 농축액의 혈청 지질 조성의 변화를 나타내는 그래프이다.1 is a graph confirming estrogen-like activity by confirming the cell proliferation by treating the concentrate of Cordyceps militaris according to an embodiment of the present invention to MCF-7 cells proliferating by estrogen stimulation.
Figure 2 is a graph confirming the estrogen-like activity by confirming the cell proliferation by treating the Queens One Tab (Queens One Tab) proliferating MCF-7 cells by estrogen stimulation.
Figure 3 is a diagram showing a Western blot result of measuring the expression of ERα and phosphorylated ERα (pERα) for confirming the estrogen receptor response of Cordyceps militaris concentrate according to an embodiment of the present invention.
Figure 4 is a graph showing the weight loss effect of the cordyceps militaris concentrate in an animal model for inducing menopausal symptoms according to an embodiment of the present invention.
FIG. 5 is a graph showing changes in dietary intake of cordyceps militaris concentrate in a female menopausal symptom induction animal model according to an embodiment of the present invention.
6 is a graph showing the change in fat content (%) of the concentrate of Cordyceps militaris in the female menopausal symptom induction animal model according to an embodiment of the present invention.
7 is a picture taken by dual energy X-ray absorptiometry of the whole body of a cordyceps militaris concentrate in a female menopausal symptom induction animal model according to an embodiment of the present invention. It means low-, medium-, and high-density fat in the order of yellow and red.
Figure 8 is a graph showing the change in the serum lipid composition of the cordyceps militaris concentrate in the female menopausal symptom induction animal model according to an embodiment of the present invention.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. 또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.Terms used in the present specification have selected general terms that are currently widely used as possible while considering functions in the present invention, but this may vary depending on the intention or precedent of a technician working in the field, the emergence of new technologies, and the like. In addition, in certain cases, there are terms arbitrarily selected by the applicant, and in this case, the meaning of the terms will be described in detail in the description of the corresponding invention. Therefore, the terms used in the present invention should be defined based on the meaning of the term and the overall contents of the present invention, not a simple name of the term.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related technology, and should not be interpreted as an ideal or excessively formal meaning unless explicitly defined in this application. Does not.
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여져 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여져 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.The numerical range includes the numerical values defined in the above range. All maximum numerical limits given throughout this specification include all lower numerical limits as if the lower numerical limits were expressly written. All minimum numerical limits given throughout this specification are inclusive of all higher numerical limits as if the higher numerical limits were expressly written. All numerical limits given throughout this specification will include all better numerical ranges within the wider numerical range, as the narrower numerical limits were expressly written.
본 발명의 이해를 돕기 위하여 실시예, 제조예를 제시한다. 하기의 실시예, 제조예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예, 제조예에 의해 본 발명의 내용이 한정되는 것은 아니다.In order to help understand the present invention, examples and manufacturing examples are presented. The following examples and preparation examples are provided for easier understanding of the present invention, and the contents of the present invention are not limited by the examples and preparation examples.
본 발명의 실시예에서 사용되는 동충하초는 대한민국 주식회사 머쉬텍에서 구입하였으며, 이하에서 언급된 시약 및 용매 등은 특별한 언급이 없는 한 Sigma-Aldrich사로부터 구입하였다.Cordyceps sinensis used in the examples of the present invention was purchased from Mustech Co., Ltd. in Korea, and the reagents and solvents mentioned below were purchased from Sigma-Aldrich unless otherwise noted.
본 발명에서 상온은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미이며, 특별한 언급이 없는 한 20℃ 내지는 30℃ 범위의 일반적인 실험실 온도를 뜻한다.In the present invention, room temperature has the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs, and means a general laboratory temperature in the range of 20°C to 30°C unless otherwise noted.
실시예Example
실시예 1: 동충하초(Example 1: Cordyceps sinensis ( Cordyceps militarisCordyceps militaris ) 농축액의 제조) Preparation of concentrate
동충하초(Cordyceps militaris) 20 kg을 추출조에 투입하였다. 추출조에 제1 추출 용매인 50%(v/v)의 에탄올 수용액 200L를 첨가한 후, 상온에서 72 시간 동안 1차 추출하였다. Cordyceps militaris 20 kg was added to the extraction tank. After adding 200L of 50% (v/v) aqueous ethanol solution as the first extraction solvent to the extraction tank, the first extraction was performed at room temperature for 72 hours.
이후, 추출조에서 액상의 용액을 분리하고, 남은 동충하초(Cordyceps militaris) 고형물이 있는 추출조에 제2 추출 용매인 50%(v/v)의 에탄올 수용액 44L를 추가로 첨가하고 4 시간 동안 2차 추출하였다.Thereafter, the liquid solution was separated in the extraction tank, and 44L of a 50% (v/v) ethanol aqueous solution was additionally added to the extraction tank with the remaining Cordyceps militaris solids, followed by secondary extraction for 4 hours. I did.
1차 추출액과 2차 추출액을 혼합하여 규조토 여과보조제를 사용하여 감압 여과하여 여과액을 수득하였다.The first extract and the second extract were mixed and filtered under reduced pressure using a diatomaceous earth filter aid to obtain a filtrate.
여과액을 65 brix 이상까지 30 mmHg 조건에서 감압 농축하여 동충하초(Cordyceps militaris) 농축액을 수득하였다.The filtrate was concentrated under reduced pressure under the condition of 30 mmHg to 65 brix or more to obtain a Cordyceps militaris concentrate.
-수득량: 1.67 kg-Yield: 1.67 kg
-수율: 8.4%-Yield: 8.4%
-코디세핀 함량: 0.976%-Codycepin content: 0.976%
측정방법How to measure
<방법 1> 동충하초(<Method 1> Cordyceps sinensis ( Cordyceps militarisCordyceps militaris ) 농축액에 함유된 코디세핀 함량 측정) Measurement of cordycepine content in concentrate
상기 실시예 1의 동충하초(Cordyceps militaris) 농축액에 함유된 코디세핀의 함량을 측정하기 위해, 하기 조건으로 HPLC 분석을 수행하였다.In order to measure the content of cordycepin contained in the concentrate of Cordyceps militaris of Example 1, HPLC analysis was performed under the following conditions.
약 100 mg의 상기 실시예 1의 동충하초(Cordyceps militaris) 농축액을 10 mL 용량 플라스크에 넣고 교반기로 교반하면서 5 mL 증류수에 용해하였다. 그 후 5 mL 에탄올을 추가하여 흔들어 섞은 다음, 20분간 초음파로 진탕하였다. 액을 식힌 후 약 1 mL을 취하여 1.5 mL EP tube에 옮겨 담고 13,000 RPM에서 5분간 원심분리하여 상등액을 검액으로 사용하였다. 20.0 mg 코디세핀을 50% 에탄올에 용해한 후, 100 mL로 정용하는 방식으로 여러 차례로 희석하여 5~ 50 μg/mL의 농도범위에서 검량용 표준용액을 조제하였다. 검액 및 표준액 10ul를 하기 표 1 조건에 따라 액체크로마토그래피를 이용하여 코디세핀의 함량을 측정하였다.About 100 mg of Cordyceps militaris concentrate of Example 1 was added to a 10 mL flask and dissolved in 5 mL distilled water while stirring with a stirrer. Thereafter, 5 mL ethanol was added, shaken, and then shaken for 20 minutes with ultrasonic waves. After cooling, about 1 mL was taken, transferred to a 1.5 mL EP tube, and centrifuged at 13,000 RPM for 5 minutes, and the supernatant was used as a sample solution. After dissolving 20.0 mg cordycepine in 50% ethanol, it was diluted several times in a manner of diagnosing to 100 mL to prepare a standard solution for calibration in a concentration range of 5 to 50 μg/mL. The content of cordycepine was measured using liquid chromatography in 10 ul of the test solution and standard solution according to the conditions in Table 1 below.
코디세핀의 함량은 검액과 표준액의 농도 및 피크 면적으로부터 검량선을 구하고, 여기에 코디세핀의 피크 면적을 대입하여 코디세핀 농도를 계산하였다. 코디세핀 함량 (%)를 계산하는 식은 하기와 같다.For the content of cordicepin, a calibration curve was obtained from the concentration and peak area of the sample solution and the standard solution, and the peak area of cordicepine was substituted to calculate the cordycepine concentration. The formula for calculating the cordycepine content (%) is as follows.
[식 1][Equation 1]
코디세핀 (C10H13N5O3)함량 (%)=(CS/WS)ⅹfⅹPCordycepine (C 10 H 13 N 5 O 3 ) Content (%) = (CS/WS) xf x P
-CS; 농축액에 함유된 코디세핀의 농도(mg/mL)-CS; The concentration of cordycepine in the concentrate (mg/mL)
-WS; 칭량한 농축액의 양(mg)-WS; Weighed Concentrate Amount (mg)
-f; 희석 배수-f; Dilution factor
-P; 코디세핀 표준품의 함량 (%/100)-P; Content of cordycepine standard product (%/100)
[표 1][Table 1]
<방법 2> 동충하초(<
상기 실시예 1의 동충하초(Cordyceps militaris) 농축액이 65 brix 이상임을 확인하기 위해 당도측정기(refractometer)에 적량을 넣어 동충하초(Cordyceps militaris) 농축액의 당도를 평가하였다.In order to confirm that the concentrate of Cordyceps militaris of Example 1 was 65 brix or higher, the sugar content of the concentrate of Cordyceps militaris was evaluated by putting an appropriate amount into a sugar content meter (refractometer).
<방법 3> MCF-7 세포의 세포 증식 평가<Method 3> Evaluation of cell proliferation of MCF-7 cells
실시예 1에 따른 동충하초(Cordyceps militaris) 농축액이 에스트로겐 활성 여부를 세포 단계에서 평가하기 위해, 여성 호르몬인 에스트로겐에 대한 증식 활성이 있는 MCF-7(Michigan Cancer Foundation-7) 세포를 이용하였다.In order to evaluate whether the cordyceps militaris concentrate according to Example 1 has estrogen activity at the cellular level, MCF-7 (Michigan Cancer Foundation-7) cells having proliferative activity for estrogen, a female hormone, were used.
MCF-7 세포는 10% dextran-coated charcoal-stripped FBS가 포함되어 있는 Phenol red-free RPMI1640배지(Gibco)에서 배양하였다. MCF-7 세포를 6 well plate에 3×105 cells/well의 농도로 분주한 후 37℃ 5% CO2 조건에서 배양하고, 24시간 후에 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액을 5, 10, 25 μg/mL 로 처리하였다. 에스트로겐 활성 효과를 비교하기 위한 양성 대조군으로 에스트로겐 활성 효과가 입증된 퀸즈원정 (경진제약사)을 처리하였다. 아무것도 처리되지 않은 상태의 세포 수 대비 각 시료를 처리한 후의 세포 수를 측정하여 세포 증식 비율(단위: %)을 측정하였다.MCF-7 cells were cultured in Phenol red-free RPMI1640 medium (Gibco) containing 10% dextran-coated charcoal-stripped FBS. After dispensing MCF-7 cells in a 6 well plate at a concentration of 3×10 5 cells/well, incubation at 37° C. 5% CO 2 condition, and after 24 hours, cordyceps militaris concentrate according to Example 1 was 5, Treated with 10 and 25 μg/mL. As a positive control for comparing the estrogen activity effect, Queen's Expedition (Kyungjin Pharmaceutical Co., Ltd.), whose estrogen activity effect was proven, was treated. The cell proliferation rate (unit: %) was measured by measuring the number of cells after each sample was treated with respect to the number of cells in the untreated state.
또한, 동충하초(Cordyceps militaris) 농축액을 에스트로겐 자극으로 증식하는 MCF-7 세포에 처리함에 따라 세포 증식 여부를 확인함으로써, 에스트로겐 유사 활성임을 확인하기 위해 MCF-7 세포에 에스트로겐 수용체의 길항제 (antagonist)인 ICI 182,780 1 μM을 각각의 농도의 시료와 동시에 처리하여 세포 증식의 변화를 측정하였다.In addition, by processing the concentrate of Cordyceps militaris on the MCF-7 cells proliferating by estrogen stimulation, the cell proliferation was confirmed, and in order to confirm the estrogen-like activity, ICI, an antagonist of the estrogen receptor in MCF-7 cells. Changes in cell proliferation were measured by simultaneously treating 182,780 1 μM with samples of each concentration.
<방법 4> MCF-7 세포의 에스트로겐 수용체 활성 평가<
실시예 1에 따른 동충하초(Cordyceps militaris) 농축액이 처리된 MCF-7 세포에서 에스트로겐 수용체의 변화를 확인하기 위해, 웨스턴 블럿으로 ERα(Estrogen receptor alpha)의 인산화 정도를 확인하였다.In order to confirm the change of estrogen receptor in MCF-7 cells treated with Cordyceps militaris concentrate according to Example 1, the degree of phosphorylation of ERα (Estrogen receptor alpha) was confirmed by Western blot.
구체적으로, MCF-7세포는 10% fetalbovine serum(FBS, Gibco), penicillin G(100 μg/mL), streptomycin sulfate(100 μg/mL)이 포함되어 있는 RPMI1640 배지(Gibco)에서 37℃온도와 5% CO2가 공급되는 습윤한 조건으로 배양하고, 동충하초 농축액을 처리하였다.Specifically, MCF-7 cells were subjected to a temperature of 37°C and 5 in RPMI1640 medium (Gibco) containing 10% fetalbovine serum (FBS, Gibco), penicillin G (100 μg/mL), and streptomycin sulfate (100 μg/mL). Incubated under humid conditions supplied with% CO 2 , and treated with Cordyceps sinensis concentrate.
1시간 배양 후 1X RIPA buffer (Tech&innovation)를 이용하여 단백질을 추출하였다. 추출한 단백질을 BCA (Bicinchoninic acid, Sigma) 정량법을 이용하여 total 단백질을 정량한 후 SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel)을 이용하여 분리하였고, 분리된 단백질을 PVDF membrane (Immobilon-P membrane, Merck Millipore)에 이동시킨 후 항체을 반응시켰다. 실험에 사용된 1차 항체는 ERα (1:2000, cell signaling), phospho-ERα (ser118) (1:2000, cell signaling), GAPDH(1:5000, cell signaling)를 사용하였고, 2차 항체는 horseradish peroxidase가 부착된 anti-mouse 항체(1:3000, cell signaling) 및 anti-rabbit 항체(1:3000, cell signaling)를 사용하였다. 밴드는 SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) 와 fusion solo (VILBER LOURMAT)를 이용하여 ERα, pERα 및 GAPDH의 발현양을 측정하였다.After incubation for 1 hour, proteins were extracted using 1X RIPA buffer (Tech&innovation). The extracted protein was quantified using the BCA (Bicinchoninic acid, Sigma) quantification method, and then the total protein was quantified and then separated using SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel). ), the antibody was reacted. The primary antibody used in the experiment was ERα (1:2000, cell signaling), phospho-ERα (ser118) (1:2000, cell signaling), and GAPDH (1:5000, cell signaling), and the secondary antibody Horseradish peroxidase-attached anti-mouse antibody (1:3000, cell signaling) and anti-rabbit antibody (1:3000, cell signaling) were used. As for the band, the expression levels of ERα, pERα and GAPDH were measured using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) and fusion solo (VILBER LOURMAT).
<방법 5> 여성 갱년기 증상 유도 동물 모델 제작 및 투여방법<
(1) 여성 갱년기 증상 유도 동물 모델 제작(1) Female menopausal symptoms induction animal model production
본 발명의 동충하초(Cordyceps militaris) 농축액의 여성 갱년기 증상 개선 효과를 확인하기 위해, 여성 갱년기 증상이 유도된 동물 모델을 제작하였다.In order to confirm the effect of improving female menopausal symptoms of the cordyceps militaris concentrate of the present invention, an animal model in which female menopausal symptoms are induced was produced.
실험에 사용된 동물은 랫드 7 주령 암컷을 사용하였으며, 수술을 실시하지 않은 정상군, 난소를 절제하지 않고 개복수술을 진행한 군(sham), 난소를 수술로 절제한 난소절제군으로 평균 체중이 동일하게 랫드를 분류하였다. 상기 방법을 통해 랫드의 난소를 절제함으로써 여성 갱년기 증상이 유도된 랫드를 준비하였다.The animals used in the experiment were rat 7-week-old females, and the average weight was a normal group without surgery, a sham group without ovarian resection, and an ovarian resection group with surgery. Rats were classified in the same way. Rats in which female menopausal symptoms were induced were prepared by resecting the rat ovaries through the above method.
(2) 투여방법(2) Method of administration
실시예 1에 따른 동충하초(Cordyceps militaris) 농축액을 난소절제군에게 37.5, 75, 150 mg/kg 용량으로 1일 1회 식이 투여하였고, 이를 동충하초(Cordyceps militaris) 농축액 투여군으로 명명하였다. Cordyceps militaris concentrate according to Example 1 was administered to the ovariectomy group at a dose of 37.5, 75, 150 mg/kg once a day, and this was named as Cordyceps militaris concentrate administration group.
효과의 비교를 위해, 음성 대조군으로 난소절제군에 증류수(DW)를 동충하초(Cordyceps militaris) 농축액 대신에 투여하였고, 이를 증류수 투여군으로 명명하였다. 또한, 양성 대조군으로 난소절제군에 β-estradiol를 0.01 mg/kg을 1일 1회 식이 투여하였고, 이를 β-estradiol 투여군으로 명명하였다.For comparison of the effects, distilled water (DW) was administered to the ovariectomy group as a negative control instead of the concentrate of Cordyceps militaris , and this was named as the distilled water administration group. In addition, 0.01 mg/kg of β-estradiol was administered once a day to the ovariectomy group as a positive control group, and this was named as the β-estradiol administration group.
<방법 6> 지방량 측정<
실시예 1에 따른 동충하초(Cordyceps militaris) 농축액이 여성 갱년기 증상 유도 동물모델에서 지방량 변화를 측정하기 위해, 각 실험군 랫드의 전신을 INALYZER(MEDIKORS)를 이용하여 이중 에너지 X 선 흡수법(the dual energy X-ray absorptiometry)으로 체지방을 분석하였다. Cordyceps militaris concentrate according to Example 1 to measure the change in fat mass in the female menopausal symptom induction animal model, the dual energy X-ray absorption method (the dual energy X) using INALYZER (MEDIKORS) whole body of each experimental rat. -ray absorptiometry) was used to analyze body fat.
<방법 7> 혈청 지질 조성 변화<Method 7> Serum lipid composition change
실시예 1에 따른 동충하초(Cordyceps militaris) 농축액이 여성 갱년기 증상 유도 동물모델에서 혈청 지질 조성에 끼치는 영향을 평가하기 위해, 각 실험군 랫드로부터 혈액을 채취하고, Accute TBA-40FR kit(Toshiba Medical Systems Co., Japan)를 이용하여 제조사의 프로토콜에 따라 트리글리세라이드(TG), 총 콜레스테롤(CHOL), 고밀도 지질 단백질(HDL) 및 저밀도 지질 단백질(LDL)의 혈중 함량을 측정하였다.In order to evaluate the effect of the cordyceps militaris concentrate according to Example 1 on the serum lipid composition in the female menopausal symptom induction animal model, blood was collected from each experimental rat, and the Accute TBA-40FR kit (Toshiba Medical Systems Co. , Japan) according to the manufacturer's protocol to measure the blood content of triglyceride (TG), total cholesterol (CHOL), high-density lipoprotein (HDL), and low-density lipoprotein (LDL).
실험예Experimental example
실험예 1: 에스트로겐 활성 평가Experimental Example 1: Estrogen activity evaluation
(1) MCF-7 세포의 세포 증식 평가 (1) Evaluation of cell proliferation of MCF-7 cells
상기 방법 3에 따라 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액을 5, 10 및 25 μg/mL 로 처리하였을 때, 각각 107.9%, 126.1% 및 135.7% 로 농도가 증가함에 따라 세포 증식 효과가 향상되는 것을 확인하였고, ICI 182,780를 동시에 처리한 경우 세포 증식이 억제되었다 (도 1 참조).When the Cordyceps militaris concentrate according to Example 1 was treated with 5, 10 and 25 μg/mL according to Method 3, the cell proliferation effect was improved as the concentration increased to 107.9%, 126.1% and 135.7%, respectively. It was confirmed that, when treated with ICI 182,780 at the same time, cell proliferation was inhibited (see FIG. 1).
또한, 양성 대조군인 퀸즈원정을 25, 50 및 100 μg/mL로 처리하였을 때, 각각 111.2%, 118.5%, 124.8%로 세포가 증식되는 것을 확인하였고, ICI 182,780를 동시에 처리한 경우 세포 증식이 억제되었다 (도 2 참조).In addition, when the positive control Queen's Expedition was treated with 25, 50 and 100 μg/mL, it was confirmed that cells proliferated at 111.2%, 118.5%, and 124.8%, respectively, and when treated with ICI 182,780 at the same time, cell proliferation was inhibited. Became (see Fig. 2).
상기의 결과를 통해 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액을 투여함에 따라 에스트로겐 자극으로 증식하는 MCF-7 세포가 증식함으로써 에스트로겐 유사 활성을 확인하였다. 또한, 에스트로겐 수용체의 길항체인 ICI 182,780와 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액을 동시에 처리하였을 때, 세포 증식이 억제되는 것을 보아, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액은 에스트로겐 수용체와 작용하는 에스트로겐 유사 활성이 있다는 것을 입증하였다.Through the above results, as the concentrate of Cordyceps militaris according to Example 1 was administered, the estrogen-like activity was confirmed by proliferating MCF-7 cells proliferating by estrogen stimulation. In addition, when treated with ICI 182,780, which is an antagonist of estrogen receptor, and the concentrate of Cordyceps militaris according to Example 1 at the same time, cell proliferation was inhibited, so that the concentrate of Cordyceps militaris according to Example 1 was prepared with It has been demonstrated that there is an estrogen-like activity that acts.
특히, 기존의 여성 갱년기 치료제인 퀸즈원정은 25 μg/mL 농도에서 MCF-7가 11.2% 증가되는 반면, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액은 25 μg/mL의 농도에서 MCF-7 세포가 35.7%로 퀸즈원정에 3배 이상 향상됨을 확인함으로써, 상기의 결과를 통해 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액은 기존의 여성 갱년기 치료제보다 에스트로겐 유사 활성이 우수하다는 것을 입증하였다.In particular, the existing female menopausal treatment, Queen's Expedition, increases MCF-7 by 11.2% at a concentration of 25 μg/mL, whereas the Cordyceps militaris concentrate according to Example 1 is MCF-7 cells at a concentration of 25 μg/mL. By confirming that the 35.7% was improved more than 3 times in the Queen's Expedition, through the above results, Cordyceps militaris concentrate according to Example 1 proved that the estrogen-like activity was superior to the existing female menopausal treatment.
(2) MCF-7 세포의 에스트로겐 수용체 활성 평가(2) Evaluation of estrogen receptor activity in MCF-7 cells
<방법 4>에 따라 MCF-7 세포에 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액 10, 25 μg/mL를 처리하고, 에스트로겐 수용체인 ERα 와 ERα의 인산화 형태인 pERα의 발현 정도를 웨스턴 블럿으로 확인하였다 (도 3 참조).According to <
ERα(Estrogen receptor alpha)는 에스트로겐에 반응하는 핵 수용체로서 MCF-7 세포에서는 에스트로겐 자극에 의해 인산화 되어 세포 증식과 같은 신호 전달을 조절하게 된다. 즉, 인산화된 ERα(pERα)이 발현된다는 것은 ERα이 에스트로겐과 동등한 자극을 받았다는 것을 의미한다. Estrogen receptor alpha (ERα) is a nuclear receptor that responds to estrogen. In MCF-7 cells, it is phosphorylated by estrogen stimulation to regulate signal transduction such as cell proliferation. In other words, the expression of phosphorylated ERα (pERα) means that ERα was stimulated equal to estrogen.
도 3을 참고하면, 동충하초(Cordyceps militaris) 농축액을 처리하였을 때, pERα이 발현되는 것을 확인하였으며, 상기의 결과를 통해 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액이 에스트로겐 수용체에 반응한다는 것을 입증하였다.Referring to FIG. 3, when treating the cordyceps militaris concentrate, it was confirmed that pERα was expressed, and through the above results, it was proved that the cordyceps militaris concentrate according to Example 1 responds to estrogen receptors. .
즉, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액은 에스트로겐 활성이 있기 때문에 여성 호르몬 저감으로 인한 여성 갱년기 증상을 치료 및 개선하는 효과가 있음을 입증하였다.That is, cordyceps militaris concentrate according to Example 1 has estrogen activity, so it has been proven that there is an effect of treating and improving female menopausal symptoms caused by female hormone reduction.
실험예 2: 여성 갱년기 증상 유도 동물 모델에서의 효과Experimental Example 2: Effect in female menopausal symptom induction animal model
(1) 체중 및 식이 변화(1) change in weight and diet
실시예 1에 따른 동충하초(Cordyceps militaris) 농축액이 여성 갱년기 증상 유도 동물모델에서 비만 유도 현상을 확인하기 위해, 8주 후 각각의 실험군의 체중 및 식이 변화를 상기 <방법 5>에 따라 측정하였다. Cordyceps militaris concentrate according to Example 1 was measured according to the <
[표 2][Table 2]
상기 표 2 및 도 4를 참고하면, 난소가 절제되어 여성 갱년기가 유도된 난소절제군은 난소를 절제하지 않고 개복수술만 진행한 군 (sham)에 비해 체중이 증가되는 것을 확인함으로써, 난소가 제거됨에 따라 유도되는 여성 갱년기 증상인 비만이 유도되었다는 것을 알 수 있다. 그러나, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액 투여군 (37.5, 75 및 150 mg/kg)에서 난소절제군에 비해 체중 증가가 억제되는 것을 확인하였다. 특히, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액 투여군 (150 mg/kg) 은 양성 대조군인 β-estradiol 투여군 보다 약 46%의 체중 증가 억제 효과가 나타났다.Referring to Tables 2 and 4, the ovarian resection group in which the female menopause was induced by resecting the ovary increased weight compared to the group (sham) who performed only laparotomy without resecting the ovary, thereby removing the ovary. It can be seen that obesity, a female menopausal symptom induced according to, was induced. However, it was confirmed that the weight gain was suppressed in the cordyceps militaris concentrate administration group (37.5, 75 and 150 mg/kg) according to Example 1 compared to the ovariectomy group. In particular, the cordyceps militaris concentrate administration group (150 mg/kg) according to Example 1 showed an effect of suppressing weight gain of about 46% than the β-estradiol administration group, which is a positive control.
또한, 각 실험군의 8주에 식이 섭취량을 측정하였다 (도 5 참조). 구체적으로, 난소절제군에서 난소를 절제하지 않고 개복수술만 진행한 군 (sham)에 비해 식이 섭취량이 증가함을 확인하였다. 그리고, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액 투여군에서 난소절제군에 비해 식이 섭취가 감소하였다.In addition, diet intake was measured at 8 weeks of each experimental group (see FIG. 5). Specifically, it was confirmed that dietary intake increased in the ovarian resection group compared to the group (sham) who performed only laparotomy without resecting the ovaries. And, in the cordyceps militaris concentrate administration group according to Example 1, dietary intake was decreased compared to the ovariectomy group.
상기 결과를 통해, 난소를 제거함으로 인해 여성 갱년기 증상이 유도된 랫드는 체중이 증가하고, 식이 섭취가 증가하여 비만이 유도되었으나, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액 투여군에서는 체중 증가가 억제되고 랫드의 비만 유도가 억제되었음을 확인하였다. 즉, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액은 여성 갱년기에 의해 유도되는 비만을 예방 및 개선하는 효과가 있다는 것을 입증하였다.Through the above results, the rats whose female menopausal symptoms were induced due to the removal of the ovaries gained weight and increased dietary intake to induce obesity, but weight gain was suppressed in the Cordyceps militaris concentrate administration group according to Example 1. It was confirmed that the induction of obesity in rats was suppressed. That is, it was proved that the cordyceps militaris concentrate according to Example 1 has the effect of preventing and improving obesity induced by female menopause.
(2) 지방량 측정(2) fat mass measurement
상기 <방법 6>에 따라 실험하였을 때, 난소절제군의 전체 지방 및 복부 지방이 난소 비 절재 랫드에 비해 증가하여 여성 갱년기 증상인 비만이 유도된 것을 확인하였다. 그러나, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액 투여군(37.5, 75 및 150 mg/kg)에서는 전체 지방량이 동충하초(Cordyceps militaris) 농축액의 투여량에 따라 감소하는 것을 확인하였다. 특히, 복부 지방은 β-estradiol 투여군에서는 큰 변화가 없었으나, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액 투여군 (150 mg/kg)에서는 지방량이 현저히 감소하는 것을 확인하였다(도 6 참조). 이러한 결과를 통해 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액이 복부 비만 개선에 우수한 효과가 있음을 입증하였다.When the experiment was conducted according to the above <
또한, 각 실험군의 랫드 전신 사진을 확인하면, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액의 투여량이 증가할수록 난소 비 절재 랫드와 유사한 형태로 변하는 것을 확인하였다(도 7 참조). 즉, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액은 여성 갱년기로 유도된 비만에 의한 외형 변화를 억제한다는 것을 입증하였다.In addition, when checking the whole body picture of the rats of each experimental group, it was confirmed that, as the dosage of the cordyceps militaris concentrate according to Example 1 increased, the shape changed to a similar form to that of the ovarian non-resected rat (see FIG. 7). That is, it was proved that the cordyceps militaris concentrate according to Example 1 inhibits changes in appearance due to obesity induced by female menopause.
(3) 혈청 지질 조성 변화(3) Serum lipid composition change
상기 <방법 6>에 따라 각 실험군의 혈청 지질 조성의 변화를 측정하였다.According to the <
[표 3][Table 3]
표 3 및 도 8을 참고하면, 난소절제군의 트리글리세라이드 및 LDL 수치가 난소 비 절제 랫드에 비해 증가하였다. 그러나, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액 투여군 (37.5, 75 및 150 mg/kg)에서는 트리글리세라이드 및 LDL 수치가 감소하였음을 확인하였다. 또한, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액 투여군 (37.5, 75 및 150 mg/kg)에서는 HDL 수치가 증가하고, 콜레스테롤 수치가 감소하였음을 확인하였다. Referring to Table 3 and FIG. 8, triglyceride and LDL levels in the ovariectomized group were increased compared to the non-ovarian resected rats. However, it was confirmed that triglyceride and LDL levels were reduced in the cordyceps militaris concentrate administration group (37.5, 75 and 150 mg/kg) according to Example 1. In addition, in the cordyceps militaris concentrate administration group (37.5, 75, and 150 mg/kg) according to Example 1, it was confirmed that HDL levels increased and cholesterol levels decreased.
상기 결과를 통해, 비만 및 혈관장애를 유도하는 트리글리세라이드 및 LDL 수치가 난소 절제로 인한 여성 갱년기에 의해 증가되었으나, 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액이 트리글리세라이드 및 LDL 수치의 향상을 억제하는 것을 입증하였다. 즉, 상기 결과들은 실시예 1에 따른 동충하초(Cordyceps militaris) 농축액은 여성 갱년기에 의해 유도되는 비만 및 혈관장애 증상을 예방 및 치료하는 효과가 있음을 입증하였다.Through the above results, the triglyceride and LDL levels inducing obesity and vascular disorders were increased by female menopause due to ovariectomy, but the concentrate of Cordyceps militaris according to Example 1 inhibited the improvement of triglyceride and LDL levels. Proved to be. That is, the above results proved that the Cordyceps militaris concentrate according to Example 1 is effective in preventing and treating obesity and vascular disorder symptoms induced by female menopause.
제조예Manufacturing example
<제조예 1> 정제의 제조<Production Example 1> Preparation of tablets
[표 4][Table 4]
상기의 성분을 혼합하고 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.Tablets were prepared by mixing the above ingredients and tableting according to a conventional tablet preparation method.
<제조예 2> 캡슐제의 제조<Production Example 2> Preparation of capsules
[표 5][Table 5]
상기의 성분을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.The above ingredients were mixed and filled into gelatin capsules according to a conventional capsule preparation method to prepare a capsule.
<제조예 3> 액상제의 제조<Production Example 3> Preparation of liquid formulation
[표 6][Table 6]
상기의 성분을 통상의 액상제의 제조방법에 따라서 혼합하고 100 ㎖의 갈색병에 충전하고 멸균시켜서 액상제를 제조하였다.The above ingredients were mixed according to a conventional method for preparing a liquid formulation, filled in a 100 ml brown bottle, and sterilized to prepare a liquid formulation.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.The above description of the present invention is for illustrative purposes only, and those of ordinary skill in the art to which the present invention pertains will be able to understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not limiting. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as being distributed may also be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is indicated by the claims to be described later, and all changes or modified forms derived from the meaning and scope of the claims and the concept of equivalents thereof should be construed as being included in the scope of the present invention.
Claims (11)
상기 동충하초(Cordyceps militaris) 농축액은 동충하초를 물, 탄소수 1 내지 4의 무수 저급 알코올 또는 탄소수 1 내지 4의 함수 저급 알코올 용매를 추출 용매로 추출된 것인 여성 갱년기 증상 예방 또는 치료용 약학적 조성물.The method of claim 1,
The cordyceps militaris concentrate is a pharmaceutical composition for preventing or treating female menopausal symptoms that is extracted from cordyceps militaris with water, anhydrous lower alcohol having 1 to 4 carbon atoms, or a hydrated lower alcohol solvent having 1 to 4 carbon atoms as an extraction solvent.
상기 동충하초(Cordyceps militaris) 농축액은 동충하초를 30%(v/v) 내지 70%(v/v)의 에탄올 수용액으로 추출된 것인 여성 갱년기 증상 예방 또는 치료용 약학적 조성물.The method of claim 2,
The cordyceps militaris concentrate is a pharmaceutical composition for preventing or treating female menopausal symptoms that is extracted from cordyceps militaris with an aqueous ethanol solution of 30% (v/v) to 70% (v/v).
상기 동충하초(Cordyceps militaris) 농축액은 코디세핀의 함량이 0.02 내지 20%(w/w)인 것인 여성 갱년기 증상 예방 또는 치료용 약학적 조성물.The method of claim 1,
The cordyceps militaris concentrate is a pharmaceutical composition for preventing or treating female menopausal symptoms in which the content of cordycepin is 0.02 to 20% (w/w).
상기 여성 갱년기 증상은 여성 호르몬 감소로 인한 것인 여성 갱년기 증상 예방 또는 치료용 약학적 조성물.The method of claim 1,
The female menopausal symptoms are due to a decrease in female hormones, a pharmaceutical composition for preventing or treating female menopausal symptoms.
상기 여성 갱년기 증상은 혈중 지질 장애, 골밀도 감소, 체지방 증가, 복부 비만, 안면홍조, 발한, 피부건조, 질건조증, 질위축, 하부 요도 위축, 질 염, 방광염, 배뇨통, 급뇨, 집중장애, 단기 기억장애, 불안, 신경과민, 기억력 감퇴, 근육통, 관절통, 골다공증 또는 그의 조합인 것인 여성 갱년기 증상 예방 또는 치료용 약학적 조성물.The method of claim 5,
The women's menopausal symptoms include blood lipid disorders, decreased bone density, increased body fat, abdominal obesity, facial flushing, sweating, skin dryness, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, urinary pain, urination, concentration disorder, short-term memory Disorder, anxiety, nervousness, memory loss, muscle pain, joint pain, osteoporosis, or a combination thereof, a pharmaceutical composition for the prevention or treatment of female menopausal symptoms.
상기 동충하초(Cordyceps militaris) 농축액은 하기 단계에 의해 수득되는 것인 여성 갱년기 증상 예방 또는 치료용 약학적 조성물:
(S1) 동충하초(Cordyceps militaris)를 제1 추출 용매를 혼합하고 추출하여 1차 추출액을 수득하는 제1차 추출 단계 및 상기 제1차 추출 단계를 거친 동충하초(Cordyceps militaris) 고형물과 제2 추출 용매를 혼합하고 추출하여 2차 추출액을 수득하는 제2차 추출 단계.The method of claim 1,
The cordyceps militaris concentrate is a pharmaceutical composition for preventing or treating female menopausal symptoms that is obtained by the following steps:
(S1) the Cordyceps (Cordyceps militaris) for the first extraction step of mixing the first extraction solvent and the extraction to give a primary extract, and rough Cordyceps an extraction step wherein the first (Cordyceps militaris) solid with the second extraction solvent A second extraction step of mixing and extracting to obtain a second extract.
상기 동충하초(Cordyceps militaris) 농축액은 하기 단계를 더 포함하여 수득하는 것인 여성 갱년기 증상 예방 또는 치료용 약학적 조성물:
(S2) 상기 1차 추출액 및 상기 2차 추출액을 규조토 여과보조제를 사용하여 감압 여과하여 여과액을 수득하는 여과 단계 및
(S3) 상기 여과액을 감압 농축하여 동충하초(Cordyceps militaris) 농축액을 수득하는 농축 단계.The method of claim 7,
The cordyceps militaris concentrate is a pharmaceutical composition for preventing or treating female menopausal symptoms, which is obtained by further comprising the following steps:
(S2) a filtration step of filtering the first extract and the second extract under reduced pressure using a diatomaceous earth filter aid to obtain a filtrate; and
(S3) Concentration step of obtaining a concentrated solution of Cordyceps militaris by concentrating the filtrate under reduced pressure.
상기 조성물은 약학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 포함하는 것인 여성 갱년기 증상 예방 또는 치료용 약학적 조성물.The method of claim 1,
The composition further comprises a pharmaceutically acceptable carrier, excipient, or diluent. A pharmaceutical composition for preventing or treating female menopausal symptoms.
상기 조성물은 액상제, 현탁제, 산제, 과립제, 정제, 캡슐제, 환제, 또는 엑스제의 형태인 것인 여성 갱년기 증상 예방 또는 치료용 약학적 조성물.The method of claim 1,
The composition is a pharmaceutical composition for the prevention or treatment of female menopausal symptoms in the form of a liquid, suspension, powder, granule, tablet, capsule, pill, or X agent.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190062648A KR20200136721A (en) | 2019-05-28 | 2019-05-28 | Composition for preventing or treating woman menopause symptoms comprising Cordyceps militaris Concentrate as an active ingredient |
| PCT/KR2019/006992 WO2020241958A1 (en) | 2019-05-28 | 2019-06-11 | Composition for preventing or treating woman menopause symptoms, comprising cordyceps militaris concentrate as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190062648A KR20200136721A (en) | 2019-05-28 | 2019-05-28 | Composition for preventing or treating woman menopause symptoms comprising Cordyceps militaris Concentrate as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200136721A true KR20200136721A (en) | 2020-12-08 |
Family
ID=73552789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190062648A KR20200136721A (en) | 2019-05-28 | 2019-05-28 | Composition for preventing or treating woman menopause symptoms comprising Cordyceps militaris Concentrate as an active ingredient |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20200136721A (en) |
| WO (1) | WO2020241958A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220105361A (en) | 2021-01-20 | 2022-07-27 | (주)뷰티나인 | Composition for preventing, improving or treating female climacteric symptoms comprising vitexin as an active ingredient |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028435A (en) * | 2021-12-17 | 2022-02-11 | 深圳晨雾健康科技有限公司 | Atomized liquid containing cordyceps militaris extract and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090088205A (en) | 2008-02-14 | 2009-08-19 | 건국대학교 산학협력단 | Composition of biji fermentation products with lactobacillus acidophillus on the prevention of menopausal obesity |
| KR20170055081A (en) | 2015-11-10 | 2017-05-19 | 한국 한의학 연구원 | A composition for preventing or treating menopausal disorder comprising Tetragonia tetragonoides (Pall.) Kuntze extract |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1322880C (en) * | 2005-09-23 | 2007-06-27 | 赵胜利 | Medicine for improving female estrogen and immunity |
| KR20110047585A (en) * | 2009-10-30 | 2011-05-09 | 주식회사 백옥생 | Anti-obesity composition comprising Cordyceps militaris extracts |
| KR20130060585A (en) * | 2011-11-30 | 2013-06-10 | 주식회사 진생사이언스 | Pharmaceutical composition comprising extract of cordyceps militaris showing an inhibitory effect of osteoclast differentiation |
| KR20130060586A (en) * | 2011-11-30 | 2013-06-10 | 주식회사 진생사이언스 | Health functional food comprising extract of cordyceps militaris showing an inhibitory effect of osteoclast differentiation |
| CN104940241B (en) * | 2015-05-29 | 2018-09-21 | 湖北圣峰药业有限公司 | A kind of selenium worm grass compound preparation of prevention climacteric metancholia of women |
-
2019
- 2019-05-28 KR KR1020190062648A patent/KR20200136721A/en active Search and Examination
- 2019-06-11 WO PCT/KR2019/006992 patent/WO2020241958A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090088205A (en) | 2008-02-14 | 2009-08-19 | 건국대학교 산학협력단 | Composition of biji fermentation products with lactobacillus acidophillus on the prevention of menopausal obesity |
| KR20170055081A (en) | 2015-11-10 | 2017-05-19 | 한국 한의학 연구원 | A composition for preventing or treating menopausal disorder comprising Tetragonia tetragonoides (Pall.) Kuntze extract |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220105361A (en) | 2021-01-20 | 2022-07-27 | (주)뷰티나인 | Composition for preventing, improving or treating female climacteric symptoms comprising vitexin as an active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020241958A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9649351B2 (en) | Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products | |
| US20100105766A1 (en) | Composition for inhibition or prevention of bone density reduction | |
| US8747917B2 (en) | Composition comprising Cudrania tricuspidata and Coix lachryma-jobi for suppressing obesity or lowering blood sugar, and use thereof | |
| KR102511361B1 (en) | Composition for Preventing, Improving or Treating Postmenopausal Syndrome Comprising Rosa rugosa Thunberg Extract | |
| US10675316B2 (en) | Composition for preventing and treating climacteric disorder containing extracts of Dendropanax morbifera LEV. as active ingredient | |
| KR20200136721A (en) | Composition for preventing or treating woman menopause symptoms comprising Cordyceps militaris Concentrate as an active ingredient | |
| KR102187335B1 (en) | Composition for improving premenstrual syndrome symptom comprising compounds isolated from Hordeum vulgare extract | |
| KR20150051845A (en) | Pharmaceutical composition and healthy food for alleviating climacteric syndrome | |
| KR20190007674A (en) | Composition comprising extracts of Opuntia Ficus Indica, Momordica charantia and Passiflora incarnata for preventing or alleviating climacterium | |
| KR20190136512A (en) | Composition for preventing or treating menopausal syndrome of women comprising Aristotelia chilensis extract, Angelica sinensis extract and Passiflora incarnata extract as an active ingredient | |
| KR20170055614A (en) | A composition for preventing or treating menopausal cardiovascular disease comprising Cuscuta japonica Chois extract | |
| KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR101050003B1 (en) | Composition for inhibiting obesity, containing the extract as an active ingredient | |
| KR100939089B1 (en) | Pharmaceutical composition comprising shikonin derivatives from Lithospermum erythrorhizon for treating or preventing diabetes mellitus. | |
| KR102541649B1 (en) | A composition for improving, preventing and treating of woman menopause related disease | |
| KR102588771B1 (en) | COMPOSITION COMPRISING EXTRACT Colpomenia sinuosa OR Colpomenia peregrina Sauvageau AS AN ACTIVE INGREDIENT FOR ALLEVIATING OR IMPROVING SYMPTOM BY ESTROGEN REDUCING | |
| KR102119672B1 (en) | Pharmaceutical composition and food composition for improving the symptoms of menopausal symptoms | |
| KR101348471B1 (en) | A composition comprising Larrea cuneifolia Cav. for the prevention and treatment of menopausal symptom | |
| KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR20180111317A (en) | A composition preventing, improving and treating comprising extract of Cornus officinalis, Pueraria lobata root and Lespedeza cuneata | |
| KR20170130082A (en) | A Composition Comprising the root extract of Achyranthes japonica NAKAI for preventing or improving the hormonal abnormal syndrome in women | |
| KR20230068357A (en) | Compositions for preventing or treating menopausal syndrome of women comprising cudrania tricuspidata extract, angelica sinensis extract and lycii radicis cortex extract as an active ingredient | |
| KR20240097394A (en) | Composition for preventing, ameliorating or treating dysmenorrhea containing extract of Aster spathulifolius as effective component | |
| KR101330688B1 (en) | Composition for treating and preventing prediabetes and diabetes containing oriental herbal extracts | |
| KR20240094854A (en) | Composition for preventing, treating, or alleviating menopausal symptoms comprising Paeonia lactiflora extract as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination |